# **Navigating Ulcerative Colitis: A Comprehensive Guide to Understanding and Managing Your Condition**

Ulcerative colitis (UC) is a complex and chronic condition that can significantly impact an individual's life. This report aims to provide a thorough understanding of ulcerative colitis, covering its nature, causes, symptoms, diagnostic methods, current treatment approaches, dietary and lifestyle management, potential complications, and the outlook for those living with the condition.

## **1\. Understanding Ulcerative Colitis: What It Is and Who It Affects**

### **1.1. What is Ulcerative Colitis (UC)? A Clear Definition**

Ulcerative colitis is a form of inflammatory bowel disease (IBD) characterized by chronic inflammation and the formation of ulcers, or open sores, within the digestive tract.1 Specifically, it affects the innermost lining (mucosa and submucosa) of the large intestine, which includes both the colon and the rectum.1 This inflammation is not a temporary issue caused by an infection that resolves; rather, it is a persistent condition requiring long-term management. The presence of ulcers is a key feature that explains many of the common symptoms, such as rectal bleeding and the passage of pus. UC is the most prevalent type of IBD, with estimates suggesting that approximately one million individuals in the United States are affected.1

The location of inflammation primarily in the superficial lining of the colon and rectum is a distinguishing characteristic of UC. This differs from Crohn's disease, the other main form of IBD, which can affect any part of the gastrointestinal (GI) tract from the mouth to the anus and can involve the entire thickness of the bowel wall.3 This specific localization in UC influences the types of symptoms experienced and the diagnostic procedures utilized, with colonoscopy playing a central role. It also means that some treatments can be administered topically, directly to the affected rectal or colonic tissue.

### **1.2. The Different Types of UC and Where They Occur**

Ulcerative colitis is classified into different types based on the location and extent of inflammation within the colon and rectum. Understanding the specific type of UC an individual has is crucial, as it directly influences the nature and severity of symptoms, the risk of certain complications, and the most appropriate treatment strategies.1

The primary types of ulcerative colitis include:

* **Ulcerative Proctitis:** In this form, inflammation is limited to the rectum, the final section of the large intestine closest to the anus, typically affecting less than 6 inches of this area.1 For many individuals with ulcerative proctitis, rectal bleeding may be the most prominent or only symptom.1 This type accounts for approximately one-third of all UC cases.6 Importantly, ulcerative proctitis is generally not associated with an increased risk of colon cancer compared to more extensive forms of the disease.6  
* **Left-Sided Colitis:** This category involves inflammation that extends from the rectum upwards into the left side of the colon. This can include the sigmoid colon (the S-shaped lower part of the colon) and the descending colon, potentially reaching as far as the splenic flexure (a bend in the colon near the spleen).1  
  * **Proctosigmoiditis** is a common subtype of left-sided colitis where inflammation is confined to the rectum and the sigmoid colon.1 Symptoms of left-sided colitis typically include bloody diarrhea, abdominal cramps and pain (often on the left side), and tenesmus, which is a persistent feeling of needing to have a bowel movement despite an empty bowel, or an inability to pass stool despite the urgency.1  
* **Extensive Colitis (also known as Pancolitis or Widespread Colitis):** This is the most widespread form of UC, where inflammation affects the entire colon, beginning in the rectum and extending beyond the splenic flexure, potentially involving the whole length of the colon.1 Individuals with extensive colitis often experience more severe symptoms, including frequent and severe bouts of bloody diarrhea, significant abdominal pain and cramping, pronounced fatigue, and substantial weight loss.1

**Table 1: Types of Ulcerative Colitis**

| Type of UC | Area Affected | Common Symptoms | Notes |
| :---- | :---- | :---- | :---- |
| **Ulcerative Proctitis** | Confined to the rectum (typically less than 6 inches from the anus) 1 | Rectal bleeding, rectal pain, urgency, tenesmus; sometimes difficulty with bowel movements 1 | Affects about one-third of UC patients.6 Not typically associated with increased cancer risk.6 |
| **Left-Sided Colitis** | Extends from the rectum up through the sigmoid and descending colon, up to the splenic flexure 1 | Bloody diarrhea, abdominal cramps and pain (often left-sided), urgency, tenesmus, weight loss, loss of appetite 1 | Includes proctosigmoiditis (rectum and sigmoid colon involvement).1 |
| **Extensive Colitis (Pancolitis/Widespread)** | Affects the entire colon, from the rectum proximally beyond the splenic flexure 1 | Severe bloody diarrhea, significant abdominal cramps and pain, fatigue, significant weight loss, fever 1 | Often the most severe form with higher likelihood of systemic symptoms. Increased risk of colon cancer with long-standing disease. |

While these types provide a framework for understanding UC, it's important to recognize that the extent of the disease can be a spectrum and may even change over time.1 For instance, inflammation that initially presents as ulcerative proctitis can sometimes extend further up the colon, potentially evolving into left-sided or even extensive colitis.9 Such proximal disease extension can be a marker of a more challenging disease course.8 This potential for evolution underscores the necessity of regular medical monitoring, even for those diagnosed with milder, more limited forms of UC, to detect any changes in disease extent that might warrant adjustments in treatment or surveillance strategies.

### **1.3. Who is at Risk? Age, Ethnicity, and Family History**

Several factors have been identified that may increase an individual's likelihood of developing ulcerative colitis, although it's crucial to remember that UC can occur in anyone, even in the absence of these specific risk factors.

* **Age:** Ulcerative colitis most commonly begins in younger individuals, typically before the age of 30\.1 Many people receive their diagnosis between the ages of 15 and 30, or in their mid-30s.2 However, the condition is not exclusive to the young; it can manifest at any point in life, and some individuals may not develop UC until after the age of 60\.1  
* **Race or Ethnicity:** While individuals of any racial or ethnic background can develop ulcerative colitis, it is observed most commonly in white people, particularly those of Ashkenazi Jewish descent, who have an even higher risk.1 Historically, UC has been more prevalent in North America and Western Europe, but its incidence is reportedly increasing in other regions of the world as well.10  
* **Family History:** A family history of inflammatory bowel disease, particularly ulcerative colitis, is a significant risk factor.1 If a close relative—such as a parent, sibling, or child—has UC, an individual's own risk of developing the condition is elevated.1 Estimates suggest that having a first-degree relative with UC can increase the risk by a factor of four, with overall risk ranging from 1.6% to 30% in such cases.4

While a family history points to a genetic component in UC, it is not a purely deterministic factor. Many individuals who develop UC have no known family history of the disease.3 Conversely, having a family member with UC does not guarantee that other relatives will develop it.4 This highlights that while genetic predisposition plays a role, it is one part of a more complex interplay of factors that contribute to the onset of ulcerative colitis. The development of UC is understood to be multifactorial, involving a combination of genetic susceptibility, immune system responses, and environmental influences.

## **2\. Why Does Ulcerative Colitis Happen? Exploring the Causes**

The precise trigger that initiates ulcerative colitis remains unknown, but research has identified several key factors that are believed to contribute to its development. It's generally understood that UC arises from a complex interplay between an individual's genetic makeup, their immune system's behavior, the composition of their gut microbiome, and various environmental influences.2

### **2.1. The Immune System's Role: An Overactive Response**

A central theory in the development of ulcerative colitis points to a malfunction or an abnormal reaction of the body's immune system.1 Normally, the immune system acts as a defense mechanism, identifying and attacking harmful invaders like viruses and bacteria. In individuals with UC, it is thought that the immune system mistakenly identifies harmless substances in the colon—such as food particles, beneficial gut bacteria, or even the cells lining the colon itself—as dangerous threats.1 This misdirected immune attack triggers an inflammatory response in the colon and rectum.

This process is often described as autoimmune in nature, meaning the body's immune defenses turn against its own healthy tissues.5 Instead of the inflammation subsiding once a perceived threat is neutralized (as would happen with a typical infection), in UC, the immune response becomes chronic and self-perpetuating.4 The body continuously sends inflammatory cells (like white blood cells) to the lining of the intestines, leading to persistent inflammation, the formation of ulcers, and the characteristic symptoms of UC.4 This ongoing, dysregulated immune activity explains why UC is classified as an "inflammatory" bowel disease and why many treatments aim to modulate or suppress this overactive immune response. The persistence of this immune attack, long after any initial trigger might have passed, is a key reason why UC is a chronic condition requiring long-term management strategies designed to break this cycle of inflammation.

### **2.2. Genetic Connections: Is UC Hereditary?**

Genetic predisposition is recognized as a significant factor in the development of ulcerative colitis.1 The observation that UC tends to run in families provides strong evidence for this hereditary component; individuals with a close relative affected by UC have a notably higher risk of developing the condition themselves.1

Research has identified numerous genetic markers and variations in dozens of specific genes that appear to be associated with an increased susceptibility to UC.3 Some of these implicated genes include *IL23R*, *IRF5*, *ABCB1*, *IL10RA*, *IL10RB*, *PTPN2*, *HNF4A*, and genes involved in T-cell regulation like *CCR7*, *CXCL10*, *CXCL9*, *IDO1*, *MMP9*, and *VCAM1*.10 These genetic variations are thought to contribute to UC in several ways. Some may compromise the integrity and protective function of the intestinal lining, making it more vulnerable to damage or penetration by gut bacteria and toxins.10 Other genetic variations may affect the regulation and function of immune cells, particularly T-cells, leading to an overactive or misdirected immune response against normal components of the gut.10

It's important to understand that the genetic basis of UC is complex and polygenic, meaning it involves multiple genes rather than a single "UC gene".10 These genes can influence different biological pathways, such as the maintenance of the gut barrier or the regulation of immune responses. This complexity explains why genetic testing is not routinely used to predict who will develop UC.11 Furthermore, the influence of specific genes may vary among different ethnic populations, with certain genetic variations being more strongly associated with UC in individuals of Asian, Black/African American, or White/European descent, respectively.11 While genetics clearly play a role, they are only one piece of the puzzle, as many individuals with UC have no family history of the disease, indicating that other factors are also essential for its development.3

### **2.3. The Gut Microbiome: A Complex Community**

The human digestive tract is home to a vast and diverse community of microorganisms, including bacteria, viruses, and fungi, collectively known as the gut microbiome.2 These microbes typically play a crucial role in digestion, nutrient absorption, and immune system development. Emerging research suggests that the gut microbiome is significantly involved in the development and progression of ulcerative colitis.2

Studies have consistently found differences in the composition and diversity of the gut microbiome in individuals with IBD, including UC, when compared to healthy individuals.12 This imbalance, often referred to as dysbiosis, might involve a reduction in beneficial bacteria, an overgrowth of potentially harmful bacteria, or a general decrease in microbial diversity. It is hypothesized that such alterations in the microbiome could trigger an abnormal immune response in genetically susceptible individuals, or that the immune system in UC patients may react inappropriately to even the normal, "friendly" bacteria residing in the colon, leading to chronic inflammation.10

The relationship between the gut microbiome and UC is likely bidirectional and complex. An altered microbiome may contribute to the initiation or perpetuation of inflammation. Conversely, the inflammatory environment within the colon in UC, as well as treatments for the condition (such as antibiotics or even dietary changes), can further disrupt the microbial balance.7 For example, damage to the intestinal barrier caused by inflammation can allow bacteria or their products to penetrate deeper into the intestinal wall, further stimulating the immune system and creating a vicious cycle of inflammation.15 While the precise mechanisms are still being investigated, the gut microbiome is a key area of focus for understanding UC pathogenesis and for developing novel therapeutic strategies, such as probiotics or fecal microbiota transplantation, although the efficacy of these approaches is still under active investigation.17

### **2.4. Environmental Factors and Potential Triggers**

While genetic predisposition and immune dysregulation are core components of ulcerative colitis, environmental factors are also believed to play a crucial role, likely interacting with an individual's genetic susceptibility and gut microbiome to trigger or influence the disease.2 These factors are diverse and reflect aspects of an individual's surroundings, lifestyle, and exposures over their lifetime.

* **Diet:** Although diet is not considered a direct cause of UC, it may influence an individual's risk of developing the condition and can certainly trigger symptoms or flare-ups in those who already have it.1 Some research suggests that diets high in saturated fats, red and processed meats, and ultra-processed foods may be associated with an increased risk of IBD, while diets rich in fruits, vegetables, and fiber may offer some protection.22  
* **Infections:** Past gastrointestinal infections have been implicated as potential triggers.3 Certain bacterial infections, such as those caused by *Salmonella*, *Campylobacter*, or *Clostridioides difficile* (C. diff), may precede the onset of UC or exacerbate existing disease.14 It's thought that an infection might initiate an immune response that, in susceptible individuals, fails to "turn off" properly, leading to chronic inflammation.13  
* **Medications:** The use of certain medications has been linked to IBD. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, are known to potentially increase the risk of developing IBD or worsening symptoms in those already diagnosed.3 Some antibiotics can also disrupt the gut microbiome and may trigger flares in some individuals.3  
* **Smoking:** The relationship between smoking and UC is complex and somewhat paradoxical. Current smokers appear to have a lower risk of developing ulcerative colitis, and some studies suggest smoking might even lessen the severity of the disease in certain individuals.3 Nicotine itself has been investigated for potential protective mechanisms, such as increasing mucus production in the colon or suppressing certain immune responses.14 However, the profound overall health hazards associated with smoking far outweigh any potential limited benefit for UC.3 Importantly, quitting smoking, while highly beneficial for general health, can sometimes lead to a flare-up of UC symptoms in former smokers.14 Healthcare professionals strongly advise against smoking for everyone, including those with UC, due to the risk of cancer, heart disease, and lung disease.  
* **Stress:** While stress does not cause ulcerative colitis, it is widely recognized as a factor that can aggravate symptoms and trigger disease flare-ups.1 Managing stress is therefore an important aspect of living with UC.  
* **Hygiene and Early Life Exposures (Hygiene Hypothesis):** Some theories suggest that modern living conditions, particularly in developed countries, might contribute to the rising incidence of IBD. The "hygiene hypothesis" posits that reduced exposure to microbes and infections in early childhood, possibly due to smaller family sizes, improved sanitation, and early antibiotic use, may lead to an improperly trained immune system that is more prone to overreacting to harmless stimuli later in life.3 Countries with better sanitation paradoxically show higher rates of UC, supporting this idea.13  
* **Air Pollution:** Emerging research indicates that exposure to environmental pollutants, including air pollution, particularly during childhood, may be associated with an increased risk of developing UC.14

Many of these environmental risk factors—such as diets high in processed foods, frequent antibiotic use in early life, and exposure to urban air pollution—are more characteristic of "Western" or industrialized lifestyles. This observation correlates with the historically higher incidence of UC in these regions and the increasing rates seen as other parts of the world adopt similar lifestyle patterns. This suggests that broader public health measures focusing on diet, judicious antibiotic use, and pollution control could potentially impact IBD rates in the long term. For individuals, it underscores the potential value of adopting dietary patterns centered on whole, unprocessed foods and being mindful of other modifiable environmental exposures where possible.

## **3\. What is Happening Inside My Body? Symptoms and Bodily Changes**

Ulcerative colitis manifests through a variety of symptoms, primarily affecting the intestines, but also potentially impacting general well-being and other organ systems. The nature and intensity of these symptoms are closely linked to the extent and severity of inflammation in the colon and rectum.

### **3.1. Common Intestinal Symptoms You Might Experience**

The hallmark symptoms of ulcerative colitis arise directly from the inflammation and ulceration of the colon's lining. These symptoms can vary significantly from one person to another and may develop gradually over time rather than appearing suddenly.1 The most frequently reported intestinal symptoms include:

* **Diarrhea:** This is often one of the most prominent symptoms. The inflamed colon is less able to absorb water from the stool, leading to frequent, loose bowel movements. This diarrhea is often accompanied by blood and/or pus due to the ulcerations in the colonic lining.1  
* **Rectal Bleeding:** Passing blood with the stool is a common and concerning sign of UC.1 The blood may be bright red or mixed in with the stool.  
* **Abdominal Pain and Cramping:** Inflammation and abnormal contractions of the bowel can cause discomfort, pain, and cramping, typically in the abdomen.1 The location of the pain can sometimes correlate with the area of the colon most affected.  
* **Rectal Pain:** Inflammation in the rectum can lead to localized pain in that area.1  
* **Urgency to Defecate:** A sudden, compelling need to have a bowel movement is a frequent complaint.1 This urgency can be disruptive to daily life.  
* **Tenesmus:** This refers to a distressing sensation of needing to pass stool even when the bowel is empty, or an inability to fully evacuate the bowels despite the urgent feeling.1 The inflamed rectum becomes highly sensitive, sending signals of fullness and the need for defecation prematurely.  
* **Mucus or Pus in Stool:** The ulcers and inflammation can produce mucus and pus, which may be visible in the stool.4

The specific combination and severity of these symptoms often depend on which part of the colon is inflamed (as discussed in Section 1.2 regarding the types of UC). For example, someone with ulcerative proctitis might primarily experience rectal bleeding and tenesmus, while someone with extensive colitis is more likely to have widespread abdominal pain and severe, bloody diarrhea. Understanding that these symptoms are a direct consequence of the underlying inflammation and ulceration helps in appreciating why treatment focuses on reducing this inflammation to achieve symptom relief and mucosal healing.

### **3.2. General Well-being Symptoms and Less Common Manifestations**

Beyond the direct effects on the intestines, ulcerative colitis can lead to a range of systemic symptoms that affect an individual's overall health and well-being. These symptoms are often a reflection of the body's response to chronic inflammation, blood loss, and impaired nutrient absorption.2

Common general symptoms include:

* **Fatigue:** A pervasive sense of tiredness and lack of energy is very common in UC and can be quite debilitating.1 This is likely due to the chronic inflammation, anemia, poor sleep, and the body's increased energy expenditure.  
* **Weight Loss and Loss of Appetite:** Reduced appetite, coupled with malabsorption of nutrients due to diarrhea and colonic inflammation, can lead to unintentional weight loss.1  
* **Fever:** A low-grade or sometimes higher fever can occur, especially during active flare-ups, as part of the body's inflammatory response.1  
* **Anemia:** Chronic blood loss from ulcerations in the colon can lead to iron deficiency anemia, characterized by a reduced number of red blood cells.1 Anemia contributes to fatigue and weakness.  
* **Nausea or Vomiting:** While less common than diarrhea, nausea and occasionally vomiting can occur, particularly if the disease is severe or if there are complications.12  
* **In Children: Failure to Grow or Delayed Development:** In pediatric cases, the chronic inflammation, nutrient malabsorption, and reduced appetite associated with UC can significantly impair normal growth and pubertal development.1

These systemic symptoms underscore that UC is not merely a localized bowel disorder. The body's resources are diverted to manage the chronic inflammation, and the digestive system's compromised function impacts nutrient availability, leading to these broader effects. Addressing these general well-being symptoms effectively requires controlling the underlying inflammation of UC.

### **3.3. How UC Affects the Colon and Rectum: Inflammation and Ulcers**

Ulcerative colitis directly impacts the structure and function of the large intestine (colon) and rectum by causing chronic inflammation and the formation of ulcers exclusively in their innermost lining (mucosa and, to a lesser extent, the submucosa).1 The inflammation typically begins in the rectum and extends proximally (upwards) in a continuous pattern, without skip lesions (areas of normal tissue interspersed with diseased tissue, which are more characteristic of Crohn's disease).26

Visually, during an endoscopic examination, the affected mucosal lining in early UC may appear hyperemic (reddened due to increased blood flow), granular (having a rough, sandpaper-like texture), and lose its normal shiny vascular pattern.16 Petechial hemorrhages (tiny, pinpoint red or purple spots caused by minor bleeding) may also be visible.16 The inflamed mucosa is often friable, meaning it is fragile and bleeds easily upon contact, for instance, with an endoscope.26

As the disease progresses or becomes more severe, ulcers develop. These are open sores on the mucosal surface. Large areas of the mucosa can become denuded, meaning the surface layer is stripped away.26 A characteristic microscopic finding in UC is the presence of crypt abscesses, which are collections of neutrophils (a type of white blood cell) within the crypts of Lieberkühn (glands in the intestinal lining).26 Chronic inflammation also leads to changes in the architecture of these crypts, such as distortion or branching.

This inflammatory process is destructive to the mucosal barrier, which normally protects the underlying intestinal tissue from the contents of the gut, including bacteria and toxins.15 When this barrier is damaged and ulcerated, it loses its protective functions. This allows intestinal microorganisms and their products to penetrate the mucosa more easily, further stimulating local inflammatory cells (like macrophages and dendritic cells) in the lamina propria (the layer beneath the epithelium).15 These activated immune cells then release more pro-inflammatory signals (cytokines and chemokines), which recruit additional immune cells to the site, thereby amplifying and perpetuating the inflammatory response.16 This creates a vicious cycle: inflammation damages the barrier, and a damaged barrier allows for increased microbial interaction with the immune system, leading to more inflammation. This understanding highlights why a key goal of UC treatment is not just symptom control but also achieving mucosal healing—the restoration of the integrity of the intestinal lining—to break this cycle and promote long-term remission.

### **3.4. Beyond the Gut: Extraintestinal Manifestations (EIMs)**

Ulcerative colitis is primarily a disease of the colon and rectum, but its effects can extend beyond the gastrointestinal tract, leading to what are known as extraintestinal manifestations (EIMs). These are conditions or symptoms that occur in other parts of the body and are associated with UC. EIMs are relatively common, affecting a significant proportion of individuals with IBD, with estimates ranging from 10% up to 50%.3 The presence of one EIM can increase the likelihood of developing others.31

These manifestations can affect various organ systems:

* **Joints (Musculoskeletal):** Arthritis is the most frequent EIM, reported in up to 40% of IBD patients.30 This can present as:  
  * **Peripheral arthritis:** Typically affecting large joints such as the knees, ankles, wrists, and elbows. It often flares in parallel with UC activity.26  
  * **Axial arthritis (Spondyloarthritis):** Affects the spine and sacroiliac joints (connecting the spine to the pelvis), causing inflammatory back pain and stiffness. This form, including ankylosing spondylitis, often runs a course independent of UC activity and may persist even if the colitis is in remission or after colectomy.3  
* **Skin (Dermatologic):** Skin problems occur in about 15-20% of individuals with IBD.30 Common skin EIMs include:  
  * **Erythema nodosum:** Characterized by tender, red, raised nodules, usually found on the shins and arms. Its activity often mirrors UC flare-ups.3  
  * **Pyoderma gangrenosum:** A more serious condition that starts as small blisters or pustules and can progress to deep, painful ulcers, often on the legs. Its course can be independent of UC activity.3  
  * **Aphthous stomatitis:** Painful recurrent mouth ulcers or canker sores.30  
  * **Sweet's syndrome:** A rare condition causing fever and painful skin lesions.31  
* **Eyes (Ophthalmologic):** Eye-related EIMs affect approximately 4-12% of IBD patients.30 These can include:  
  * **Uveitis:** Inflammation of the uvea (the middle layer of the eye, including the iris). Can cause eye pain, redness, blurred vision, and light sensitivity. Often requires urgent ophthalmologic attention and can run an independent course from UC activity.3  
  * **Episcleritis:** Inflammation of the episclera (the outer layer of the white of the eye), causing redness and mild discomfort. Usually parallels UC activity.30  
  * **Keratopathy and dry eyes** can also occur.30  
* **Liver and Bile Ducts (Hepatobiliary):**  
  * **Primary Sclerosing Cholangitis (PSC):** An uncommon but serious EIM, affecting about 2-7% of UC patients 32, though some sources suggest up to 5% of IBD patients overall.30 PSC involves chronic inflammation and scarring (sclerosis) of the bile ducts, both inside and outside the liver. This can obstruct bile flow, leading to liver damage, cirrhosis, and an increased risk of bile duct cancer (cholangiocarcinoma) and colorectal cancer in patients with UC.3 PSC typically runs an independent course from UC and is not cured by colectomy.31  
  * **Autoimmune hepatitis:** The immune system attacks liver cells.30  
* **Bones (Skeletal):**  
  * **Osteoporosis and Osteopenia:** Reduced bone density, leading to an increased risk of fractures. This can be due to chronic inflammation, malabsorption of calcium and vitamin D, or prolonged use of corticosteroid medications.1  
* **Blood (Hematologic):**  
  * **Anemia:** As previously mentioned, due to chronic blood loss and inflammation.1  
  * **Thromboembolism:** An increased risk of developing blood clots in veins (deep vein thrombosis, DVT) and arteries (which can lead to pulmonary embolism or stroke).1  
* **Kidneys (Renal):**  
  * **Kidney stones** may be more common in individuals with IBD.31  
* **Lungs and Heart (Pulmonary/Cardiac \- Rare):** In cases of severe UC, respiratory symptoms like shortness of breath or cardiac issues like rapid heart rate can occur, though these are less common EIMs.30

**Table 2: Common Extraintestinal Manifestations (EIMs) of Ulcerative Colitis**

| Body System Affected | Common Manifestation(s) | Brief Description of Manifestation | Typical Relationship to UC Activity |
| :---- | :---- | :---- | :---- |
| **Joints** | Peripheral arthritis | Inflammation, pain, swelling in large joints (knees, ankles, wrists, elbows) 30 | Often parallels UC flares 31 |
|  | Axial arthritis (Spondyloarthritis/Ankylosing Spondylitis) | Inflammation, pain, stiffness in the spine and sacroiliac joints 26 | Often independent of UC activity 31 |
| **Skin** | Erythema nodosum | Tender, red, raised nodules, usually on shins or arms 30 | Often parallels UC flares 31 |
|  | Pyoderma gangrenosum | Begins as small pustules/blisters, evolves into deep, painful ulcers, often on legs 33 | Can be independent of UC activity 34 |
|  | Aphthous stomatitis | Painful mouth ulcers (canker sores) 30 | Often parallels UC flares |
| **Eyes** | Uveitis/Iritis | Inflammation of the uvea/iris; causes pain, redness, blurred vision, light sensitivity 26 | Often independent of UC activity 31 |
|  | Episcleritis | Inflammation of the outer layer of the white of the eye; causes redness, mild discomfort 30 | Often parallels UC flares 31 |
| **Liver/Bile Ducts** | Primary Sclerosing Cholangitis (PSC) | Chronic inflammation and scarring of bile ducts, leading to potential liver damage/failure, increased cancer risk 3 | Independent of UC activity; not cured by colectomy 31 |
| **Bones** | Osteoporosis/Osteopenia | Reduced bone density, increased fracture risk 1 | Related to chronic inflammation, malabsorption, steroid use |
| **Blood** | Anemia | Low red blood cell count due to chronic blood loss 1 | Related to UC activity/severity |
|  | Thromboembolism | Increased risk of blood clots in veins and arteries 1 | Associated with active inflammation |

The relationship between EIMs and UC activity is important. Some EIMs, like peripheral arthritis and erythema nodosum, tend to flare up when the colitis is active and improve as the bowel inflammation is controlled.31 Others, such as axial arthritis (ankylosing spondylitis), uveitis, and primary sclerosing cholangitis, can follow a course independent of the gut inflammation.31 These independent EIMs may persist or even first appear when UC is in remission or even after surgical removal of the colon (colectomy). This distinction influences treatment decisions, as EIMs that parallel gut disease may respond to therapies aimed at UC, while independent EIMs often require their own specific treatments. Recognizing these potential EIMs is crucial for comprehensive care, allowing for early detection and management.

## **4\. Getting a Diagnosis: The Path to Clarity**

The journey to an ulcerative colitis diagnosis is a methodical process involving several steps. The primary aims are to definitively confirm the presence of UC, assess its current severity and the extent of colonic involvement, and, crucially, to rule out other conditions that can present with similar symptoms.1 This process often begins with a visit to a primary care physician, who may then refer the individual to a gastroenterologist, a specialist in diseases of the digestive system, for further evaluation and management.41

The diagnostic approach is essentially one of both inclusion (identifying features characteristic of UC) and exclusion (eliminating other possible causes for the symptoms). Conditions such as infections (like bacterial gastroenteritis or parasitic infections), irritable bowel syndrome (IBS), and Crohn's disease can have overlapping symptoms with UC, making a thorough evaluation essential for an accurate diagnosis and the subsequent selection of appropriate treatment.1

### **4.2. Key Diagnostic Tests: Medical History, Physical Exam, Blood Tests, Stool Analysis, Endoscopy (Colonoscopy/Sigmoidoscopy), and Biopsy**

A combination of assessments and tests is used to build a comprehensive picture and arrive at a diagnosis of ulcerative colitis.

* **Medical and Family History:** The diagnostic process typically starts with a detailed discussion of the individual's symptoms, including their onset, duration, frequency, and severity.42 The doctor will inquire about overall health, past medical conditions, any medications being taken (including over-the-counter drugs and supplements), recent travel history (to rule out infectious causes of diarrhea), and dietary habits.1 A crucial component is the family history, specifically whether any close relatives have been diagnosed with IBD or other autoimmune conditions.1 Lifestyle factors, such as smoking, will also be discussed.42  
* **Physical Examination:** A physical exam helps the doctor assess the individual's general health status and look for signs related to UC or its potential complications.41 This may include:  
  * Measuring vital signs (blood pressure, heart rate, temperature).42  
  * Listening to sounds within the abdomen using a stethoscope.42  
  * Gently pressing on the abdomen to check for tenderness, pain, or any abnormal masses.42  
  * A digital rectal examination may be performed to check for tenderness or blood in the rectum.42  
  * Checking for signs of extraintestinal manifestations, such as inflammation in the eyes, sores in the mouth, skin rashes, or joint swelling.45  
* **Blood Tests:** While blood tests cannot diagnose UC on their own, they provide valuable information about the individual's overall health and can point towards inflammation or complications associated with UC.42 Common blood tests include:  
  * **Complete Blood Count (CBC):** To check for anemia (low red blood cell count or hemoglobin), which can result from chronic blood loss, and to look for an elevated white blood cell count, which can indicate infection or inflammation.27  
  * **Inflammatory Markers:** Tests like C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) measure general levels of inflammation in the body.27 Elevated levels are common in active UC.  
  * **Liver Function Tests:** To assess liver health, particularly important if primary sclerosing cholangitis (PSC) is suspected.47  
  * **Electrolyte and Kidney Function Panel:** To check for imbalances that can occur with severe diarrhea and to assess kidney function.47  
  * **Nutritional Markers:** Tests for iron, vitamin B12, vitamin D, and albumin can indicate nutritional deficiencies or malabsorption.27  
  * **Serological Markers:** Tests for specific antibodies, such as perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), may be performed. pANCA is found in a majority of individuals with UC (60-80%) and, particularly when present alongside a negative ASCA (anti-Saccharomyces cerevisiae antibody, more common in Crohn's disease), can be suggestive of UC, though it's not definitive for diagnosis on its own.48  
* **Stool Studies (Fecal Analysis):** Stool samples are analyzed for several purposes:  
  * **To Rule Out Infections:** Testing for bacteria (e.g., *Clostridioides difficile*, *Salmonella*, *Campylobacter*), viruses, and parasites is crucial, as these can cause symptoms similar to a UC flare.2  
  * **To Detect Occult Blood:** Testing for microscopic amounts of blood not visible to the naked eye.45  
  * **To Measure Markers of Intestinal Inflammation:**  
    * **Fecal Calprotectin or Lactoferrin:** These are proteins released by white blood cells in the gut. Elevated levels in the stool are strong indicators of active intestinal inflammation, such as that seen in IBD.44 While not diagnostic for UC specifically (as other inflammatory conditions can also raise levels), a high fecal calprotectin level can increase the suspicion of IBD and help guide the decision to proceed with more invasive tests like colonoscopy.44 Conversely, a normal level may make active IBD less likely.  
    * **White Blood Cells in Stool:** Their presence can also indicate inflammation.43  
* **Endoscopic Procedures with Biopsy:** These are considered the gold standard for diagnosing ulcerative colitis, allowing direct visualization of the colon and rectum and tissue sampling.1  
  * **Colonoscopy:** This procedure involves inserting a colonoscope—a long, thin, flexible tube with a light and camera on the end—through the anus to examine the entire length of the colon and rectum.2 Bowel preparation with laxatives is required beforehand to clear the colon for optimal viewing.41 During colonoscopy, the doctor looks for characteristic signs of UC, such as redness, swelling, granularity of the mucosa, loss of the normal blood vessel pattern, friability (tissue that bleeds easily), and ulcers.26 The extent and severity of the inflammation can also be assessed.  
  * **Flexible Sigmoidoscopy:** Similar to a colonoscopy, but uses a shorter scope (sigmoidoscope) to examine only the rectum and the lower part of the colon (sigmoid colon).2 This may be performed if a full colonoscopy is not immediately necessary or if the colon is severely inflamed, making a full colonoscopy riskier.41  
  * **Biopsy:** During either procedure, small tissue samples (biopsies) are taken from multiple areas of the colon and rectum, including both inflamed and normal-appearing tissue.1 These biopsies are then examined under a microscope by a pathologist. The histological (microscopic) findings, such as the presence of crypt abscesses, chronic inflammatory cell infiltrates, and architectural distortion of the crypts, are crucial for confirming the diagnosis of UC and distinguishing it from other conditions like Crohn's disease or infectious colitis.26 A biopsy is essential for a definitive diagnosis.1  
* **Imaging Procedures:** While not typically the primary tools for diagnosing UC itself, imaging tests can be important in certain situations:  
  * **Abdominal X-ray:** May be used in cases of severe symptoms to quickly rule out serious complications like a perforated colon or toxic megacolon (a severely dilated colon).28  
  * **Computed Tomography (CT) Scan:** A CT scan of the abdomen or pelvis might be performed if a complication of UC is suspected, or to help assess the extent of inflammation, particularly if a full colonoscopy cannot be completed.43  
  * **Magnetic Resonance Imaging (MRI) or CT Enterography:** These specialized imaging tests are more often used to evaluate the small intestine, which is particularly relevant if Crohn's disease is a possibility, as UC primarily affects the large intestine.43 MR enterography has the advantage of not using ionizing radiation.

The diagnostic process for ulcerative colitis is a comprehensive evaluation, where each component—from the initial medical history to the definitive findings of endoscopy and biopsy—contributes essential pieces to the overall picture. Blood tests and stool studies often provide indirect evidence or help rule out other conditions, with fecal calprotectin emerging as a useful non-invasive marker to assess the likelihood of intestinal inflammation and guide further investigation.44 Ultimately, the direct visualization afforded by endoscopy, combined with the microscopic examination of tissue biopsies, provides the most conclusive evidence for establishing a diagnosis of ulcerative colitis.1 This thorough, multi-step approach is necessary due to the overlapping symptoms with other gastrointestinal disorders and ensures that the management plan is tailored to the correct condition.

## **5\. Managing Ulcerative Colitis: A Comprehensive Treatment Approach**

The management of ulcerative colitis is multifaceted, aiming not only to alleviate current symptoms but also to achieve long-term control of the disease, prevent complications, and improve the individual's overall quality of life. Treatment strategies are typically individualized based on the severity and extent of the disease, as well as the person's response to previous therapies and their overall health status.8

### **5.1. Goals of Treatment: Achieving and Maintaining Remission**

The overarching goals of ulcerative colitis treatment are to:

* **Induce Remission:** This means bringing active inflammation under control and significantly reducing or eliminating symptoms such as diarrhea, rectal bleeding, and abdominal pain.5  
* **Maintain Remission:** Once symptoms are controlled, the aim is to keep the disease inactive for as long as possible, preventing flare-ups or relapses.5  
* **Achieve Mucosal Healing:** Increasingly, a key therapeutic target is the healing of the lining of the colon and rectum, as observed during endoscopy. Mucosal healing is associated with better long-term outcomes, including reduced risks of hospitalization, surgery, and colorectal cancer.53  
* **Improve Quality of Life:** Reducing symptoms and controlling inflammation should translate into an improved ability to engage in daily activities, work, and social life.40  
* **Prevent Complications:** Long-term management seeks to minimize the risk of complications associated with UC, such as severe bleeding, perforation, toxic megacolon, and the development of colorectal cancer.29  
* **Minimize Medication Side Effects:** While medications are crucial, the goal is to use them in a way that maximizes benefits while minimizing potential adverse effects, often through steroid-sparing strategies.40

The concept of "remission" in UC has evolved. While clinical remission (the absence of symptoms) is a primary patient concern, healthcare providers also focus on deeper levels of remission, such as endoscopic remission (no visible inflammation on colonoscopy) and even histological remission (no signs of inflammation when tissue samples are examined under a microscope).55 Achieving these deeper states of remission is believed to lead to more sustained disease control and a more favorable long-term prognosis.54 This often requires ongoing medication even when an individual feels well, and periodic monitoring, including colonoscopies, to assess the level of inflammation.50

### **5.2. Medications to Control Inflammation and Symptoms**

A variety of medications are available to treat ulcerative colitis. The choice of drug therapy depends on the severity and location of the inflammation, as well as how an individual has responded to previous treatments.8 It is common for individuals to require lifelong medication to manage UC unless they undergo surgical removal of the colon and rectum.50

#### **5.2.1. Aminosalicylates (5-ASAs)**

* **Examples:** This class includes medications such as sulfasalazine (Azulfidine), and various formulations of mesalamine (also known as mesalazine or 5-aminosalicylic acid), such as Asacol®, Lialda®, Pentasa®, Salofalk®, Delzicol®, Octasa®, and Mezavant®. Other 5-ASAs are olsalazine (Dipentum) and balsalazide (Colazal).43  
* **Mechanism of Action:** Aminosalicylates are believed to exert their anti-inflammatory effect directly on the lining of the colon and rectum.56 While the precise mechanism is not fully understood, they are thought to modulate local inflammatory pathways, possibly by inhibiting the production of inflammatory substances like prostaglandins and leukotrienes through the cyclooxygenase and lipoxygenase pathways.56  
* **Use and Efficacy:** 5-ASAs are typically the first line of treatment for individuals with mild to moderate ulcerative colitis and are used both to induce remission during a flare-up and to maintain remission once achieved.43 They are considered highly effective for these purposes, with studies showing a significant benefit over placebo.58 For instance, one meta-analysis indicated a number needed to treat (NNT) of 6 to achieve remission and an NNT of 4 to prevent relapse.58 Doses of 2.0 grams per day or higher are generally found to be more effective for both induction and maintenance.58 The formulation and route of administration depend on the location of the inflammation.43 Topical preparations, such as suppositories or enemas, are often used for ulcerative proctitis (inflammation confined to the rectum) or proctosigmoiditis (inflammation in the rectum and sigmoid colon) as they deliver the medication directly to the affected area.43 Oral formulations, which are designed with various coatings to release the medication at different points in the colon, are used for more extensive disease.56 This variety in formulations allows for targeted drug delivery, optimizing efficacy based on where the inflammation is most active. If one specific 5-ASA product or formulation is not effective or causes side effects, a different one might be better tolerated or more successful.  
* **Side Effects:** 5-ASAs are generally well-tolerated by most individuals, as they are designed to act locally in the gut with minimal systemic absorption.59 Common side effects are usually mild and can include diarrhea, headache, nausea, and rash.56 Sulfasalazine, one of the older 5-ASAs, contains a sulfa component (sulfapyridine) that is responsible for a higher incidence of side effects compared to newer mesalamine-only formulations. These can include dose-related issues, allergic reactions (especially in those with sulfa allergies), reversible reduction in male fertility (due to decreased sperm counts), and impaired absorption of folic acid (requiring supplementation, especially during pregnancy).59 Rare but more serious side effects associated with aminosalicylates (primarily mesalamine components) can include inflammation of the kidneys (interstitial nephritis), pancreas (pancreatitis), lungs (pneumonitis), or liver (hepatitis), and blood disorders such as agranulocytosis (a severe drop in white blood cells) or aplastic anemia.56 It is crucial to report any unexplained bleeding, bruising, persistent sore throat, fever, or general unwellness to a doctor immediately, as these could be signs of a serious blood-related side effect.56 Individuals with a known allergy to salicylates (like aspirin) or with certain pre-existing severe liver or kidney problems may not be suitable candidates for 5-ASA therapy.56

#### **5.2.2. Corticosteroids**

* **Examples:** This group includes prednisone (Deltasone), budesonide (Entocort EC, Uceris), hydrocortisone, and methylprednisolone.43  
* **Mechanism of Action:** Corticosteroids are potent, broad-spectrum anti-inflammatory drugs that work by suppressing the overall immune system, thereby reducing inflammation throughout the body.60 Their action is not targeted to specific inflammatory pathways but rather has a widespread effect.  
* **Use and Efficacy:** Corticosteroids are primarily used for managing moderate to severe flare-ups of ulcerative colitis, especially when 5-ASA medications are not sufficient to control the inflammation.43 They are highly effective at rapidly reducing inflammation and inducing clinical remission, often leading to quick improvement in symptoms.61 Studies have shown that corticosteroids can induce complete remission in about 54% of patients and partial remission in another 30% within 30 days of starting treatment.61 They can be administered orally (pills), intravenously (for severe, hospitalized cases requiring rapid and high-dose treatment), or rectally (as enemas, foams, or suppositories for disease limited to the rectum or left side of the colon).61 Budesonide is a type of corticosteroid designed with a special coating (e.g., Uceris for UC) or formulation (e.g., Entocort EC, primarily for Crohn's affecting the ileum/right colon but sometimes used off-label or in specific UC contexts) that allows for more targeted release in the gut. It also undergoes extensive first-pass metabolism in the liver, meaning much of the drug is broken down before it reaches the systemic circulation, resulting in fewer systemic side effects compared to traditional corticosteroids like prednisone.61 Despite their effectiveness in acute flares, corticosteroids are not suitable for long-term maintenance of remission due to the risk of significant side effects.61 Furthermore, not everyone responds to steroids; up to one-third of individuals may be "steroid-refractory" (meaning the drugs don't work well for them), and a portion (around 22%) may become "steroid-dependent," meaning their symptoms return as soon as the steroid dose is lowered, making it difficult to discontinue the medication.61  
* **Side Effects:** The use of corticosteroids is associated with a wide range of potential side effects, particularly with prolonged use or high doses. These are a major limiting factor in their application.  
  * **Short-term side effects** can include fluid retention (leading to a rounded "moon face"), weight gain due to increased appetite, mood swings (such as irritability, anxiety, depression, or euphoria), difficulty sleeping (insomnia), acne, increased facial or body hair, stomach upset, and an increased susceptibility to infections (like urinary tract infections or oral/vaginal yeast infections).60  
  * **Long-term side effects** can be more serious and include osteoporosis (thinning and weakening of the bones), cataracts and glaucoma (eye conditions), high blood pressure (hypertension), high blood sugar (potentially leading to or worsening diabetes), muscle weakness or wasting, thinning of the skin leading to easy bruising and stretch marks, impaired wound healing, and suppression of the adrenal glands' natural steroid production.60 In children, prolonged steroid use can lead to growth retardation.61  
* **Considerations:** Because of this extensive side effect profile, corticosteroids are typically prescribed for the shortest possible duration needed to control a flare-up, usually not exceeding 8 weeks for oral courses.63 The dose is then gradually tapered down rather than stopped abruptly to allow the body's natural steroid production to recover and to prevent a rebound of symptoms.61 Individuals taking steroids should carry a steroid treatment card and be cautious about exposure to infections like chickenpox or shingles, as their immune system is suppressed.62 Corticosteroids are often viewed as a "bridge" therapy—highly effective for gaining rapid control of severe inflammation, but the long-term strategy involves transitioning to safer maintenance medications to keep the disease in remission and avoid prolonged steroid exposure. This "steroid-sparing" approach is a fundamental principle in modern UC management, as the need for frequent or prolonged corticosteroid use is associated with poorer long-term outcomes, including an increased risk of requiring colectomy.40

#### **5.2.3. Immunomodulators (Thiopurines, Methotrexate)**

Immunomodulators are medications that modify the activity of the immune system to reduce chronic inflammation. They are generally used for long-term management of ulcerative colitis, particularly to help maintain remission and reduce the need for corticosteroids (a steroid-sparing effect).43 These drugs typically take several weeks to months to reach their full therapeutic effect.66

* **Thiopurines:**  
  * **Examples:** Azathioprine (Azasan, Imuran) and 6-mercaptopurine (6-MP, Purinethol, Purixan) are the most commonly used thiopurines for IBD.43 Azathioprine is a prodrug that is converted in the body to 6-MP.  
  * **Mechanism of Action:** Thiopurines interfere with the production of DNA in rapidly dividing cells, including activated immune cells (specifically T-lymphocytes) that drive inflammation. By inhibiting purine synthesis (essential building blocks for DNA), they reduce the proliferation of these inflammatory cells.65  
  * **Use and Efficacy in UC:** Thiopurines are effective for maintaining remission in UC and are often used in patients who have had difficulty tapering off corticosteroids or who have frequent relapses.43 Pooled data and meta-analyses suggest a benefit for maintaining corticosteroid-free remission, with one analysis showing azathioprine to be superior to placebo (Odds Ratio 0.41 for failure to maintain remission) and a number needed to treat of 5 to prevent one recurrence.66 They can be used as monotherapy or, increasingly, in combination with biologic therapies to enhance the biologic's effectiveness and reduce the likelihood of the body developing antibodies against the biologic drug.65  
  * **Side Effects and Monitoring:**  
    * Common side effects include nausea, vomiting, fatigue, and a general feeling of malaise, particularly when starting the medication.60  
    * More serious potential side effects require careful monitoring. These include:  
      * **Bone marrow suppression:** A decrease in the production of blood cells (white blood cells, red blood cells, platelets), most notably leukopenia (low white blood cell count), which increases the risk of infections. This occurs in 2-15% of patients.60 Regular blood tests (complete blood counts) are essential to monitor for this.  
      * **Liver inflammation (hepatotoxicity):** Can occur in 3-10% of patients; liver function tests are monitored regularly.60  
      * **Pancreatitis:** Inflammation of the pancreas, which requires immediate discontinuation of the drug.60  
      * **Allergic reactions:** Rash, fever.60  
      * **Increased risk of infections:** Due to immunosuppression.65  
      * **Increased sensitivity to sunlight:** Sun protection is advised.52  
      * **Long-term risks:** A small increased risk of certain cancers, particularly lymphoma and non-melanoma skin cancer, has been associated with long-term thiopurine use.52 The benefits are generally considered to outweigh these risks in appropriately selected patients, but regular skin checks are often recommended.  
    * **TPMT Testing:** Before starting thiopurines, a blood test to measure the activity of an enzyme called thiopurine methyltransferase (TPMT) is often performed.66 Individuals with low or absent TPMT activity metabolize these drugs differently and are at a much higher risk of severe bone marrow suppression. Dose adjustments or avoidance of the drug are necessary in such cases. This testing helps to personalize dosing and improve safety.  
* **Methotrexate (MTX):**  
  * **Mechanism of Action:** Methotrexate inhibits the enzyme dihydrofolate reductase, which is involved in folic acid metabolism. This interference reduces the synthesis of DNA and RNA, thereby impairing the proliferation of immune cells and exerting anti-inflammatory effects.65 It is often prescribed with folic acid supplementation to reduce the risk of certain side effects like mouth sores and nausea.60  
  * **Use and Efficacy in UC:** While methotrexate is an established treatment for Crohn's disease and other autoimmune conditions like rheumatoid arthritis, its role in ulcerative colitis is less clear and more controversial.65 Current evidence and guidelines generally suggest limited or no benefit for methotrexate when used as a standalone therapy (monotherapy) for either inducing or maintaining remission in UC.65 Meta-analyses and Cochrane reviews have not consistently demonstrated its efficacy over placebo for UC.68 The European Crohn's and Colitis Organisation (ECCO) has noted that trials are ongoing 52, but as of now, it is not a standard first-line or well-established maintenance therapy for UC in the same way it is for Crohn's disease. If considered, it's often in specific situations or as part of clinical trials.  
  * **Side Effects and Monitoring:**  
    * Common side effects include nausea, vomiting, diarrhea, mouth sores, headache, and fatigue.60  
    * More serious potential side effects include:  
      * **Liver toxicity (hepatotoxicity):** Can range from elevated liver enzymes to, rarely, liver fibrosis or cirrhosis with long-term use. Regular liver function tests are required.52  
      * **Bone marrow suppression:** Leading to low blood counts and increased infection risk.60  
      * **Lung inflammation (pneumonitis):** A rare but serious complication.60  
      * **Hair loss (alopecia)**.69  
    * Methotrexate is contraindicated in pregnancy due to its teratogenic effects (risk of birth defects) and should be avoided by both men and women planning conception. Effective contraception is essential during and for a period after treatment. It also should not be used in individuals with significant kidney or liver impairment, or severe anemia.

The therapeutic window for immunomodulators like thiopurines requires careful management. Dosing must be optimized to achieve efficacy while minimizing the risk of significant side effects, necessitating regular blood monitoring (e.g., for blood counts and liver function).65 The introduction of TPMT testing for thiopurines has been a significant step in personalizing therapy and reducing the risk of myelosuppression for some individuals. However, given the potential for side effects and the advent of more targeted therapies, the precise role of these traditional immunomodulators in the UC treatment algorithm continues to evolve, with a trend towards more selective use.67 If methotrexate is considered for UC, it is particularly important for the patient to understand the limited evidence supporting its use as monotherapy in this specific condition and to discuss the rationale with their physician.

#### **5.2.4. Biologic Therapies (Anti-TNF, Anti-Integrin, Anti-Interleukin)**

Biologic therapies represent a significant advancement in the treatment of moderate to severe ulcerative colitis, particularly for individuals who have not responded adequately to, or are intolerant of, conventional therapies like 5-ASAs, corticosteroids, or immunomodulators.43 These are genetically engineered proteins, typically monoclonal antibodies, designed to target specific molecules or cells in the immune system that play a key role in driving the inflammatory process in UC.70 This targeted approach differs from the broader immunosuppression caused by corticosteroids or traditional immunomodulators. Biologics can induce and maintain clinical remission, promote healing of the intestinal lining (mucosal healing), reduce the need for corticosteroids and hospitalizations, and potentially decrease the likelihood of surgery.52

* **Types, Examples, and Mechanisms:**  
  * **Anti-TNF (Tumor Necrosis Factor) Agents:**  
    * **Mechanism:** Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine (a signaling protein) that plays a central role in the inflammatory cascade of UC. Anti-TNF agents bind to and neutralize TNF-α, thereby reducing inflammation.71  
    * **Examples:**  
      * **Infliximab (Remicade):** Administered via intravenous (IV) infusion.43  
      * **Adalimumab (Humira):** Administered via subcutaneous (under the skin) self-injection.43  
      * **Golimumab (Simponi):** Administered via subcutaneous self-injection.43  
    * **Biosimilars:** Biologically similar versions of these original biologics are available (e.g., infliximab-dyyb \[Inflectra\], adalimumab-atto \[Amjevita\]) and are considered to have comparable efficacy and safety.70  
  * **Anti-Integrin Agents (Integrin Receptor Antagonists):**  
    * **Mechanism:** These drugs target integrins, which are proteins on the surface of white blood cells. By blocking specific integrins (like α4β7 integrin), these therapies prevent inflammatory cells from migrating from the bloodstream into the gut tissue, thereby reducing inflammation in a more gut-selective manner.53  
    * **Example:**  
      * **Vedolizumab (Entyvio):** Targets the α4β7 integrin, making its action largely specific to the gastrointestinal tract. Administered via IV infusion.43  
  * **Anti-Interleukin (IL-12/23 or IL-23) Agents:**  
    * **Mechanism:** Interleukins (IL) are a group of cytokines. These agents block the activity of specific interleukins, such as IL-12 and IL-23, which are involved in promoting inflammatory responses mediated by T-cells.53  
    * **Examples:**  
      * **Ustekinumab (Stelara):** Targets both IL-12 and IL-23. Typically involves an initial IV induction dose followed by subcutaneous self-injections for maintenance.43  
      * **Risankizumab (Skyrizi):** Specifically targets IL-23. Administered by IV infusion for induction and subcutaneous injection for maintenance.43 Recently approved for UC.  
      * **Mirikizumab (Omvoh):** Specifically targets the p19 subunit of IL-23. Recently approved for UC.43  
      * **Guselkumab (Tremfya):** Specifically targets IL-23. Recently FDA-approved for UC following studies showing its efficacy.74  
* **Efficacy:** Biologic therapies have demonstrated significant efficacy in inducing and maintaining remission in patients with moderate to severe UC.53 Clinical trial data show varying remission rates for different biologics, typically ranging from around 17% to 45% for achieving remission after one year of treatment, compared to placebo.73 Network meta-analyses, which compare multiple treatments indirectly, suggest that some newer agents, including certain JAK inhibitors (discussed next) and newer biologics like risankizumab and guselkumab, may rank highly in terms of achieving specific efficacy endpoints like clinical remission, endoscopic improvement, or mucosal healing.53 However, individual responses can vary, and what works for one person may not work for another.  
* **Side Effects and Considerations:**  
  * **Common Side Effects:**  
    * **Injection site reactions:** For subcutaneously administered biologics, common reactions include redness, pain, swelling, or itching at the injection site.70  
    * **Infusion reactions:** For intravenously administered biologics, reactions during or shortly after the infusion can occur, manifesting as fever, chills, headache, rash, or shortness of breath.60 Pre-medication can sometimes prevent these.  
    * Headache, rash, and upper respiratory tract infections are also commonly reported.60  
  * **Increased Risk of Infections:** Because biologics modulate the immune system, they can increase the susceptibility to infections, including common infections like colds or flu, but also more serious infections such as tuberculosis (TB), fungal infections, or opportunistic infections.60 Screening for latent TB is standard practice before starting anti-TNF therapy. Vedolizumab, due to its gut-selective mechanism, is generally associated with a lower risk of systemic infections compared to anti-TNF agents.70  
  * **Immunogenicity (Antibody Development):** The body can sometimes develop antibodies against biologic drugs, as they are proteins. This is known as immunogenicity. The development of these anti-drug antibodies can lead to a loss of response to the medication over time or increase the risk of infusion/injection reactions.65 This is one reason why biologics are sometimes used in combination with an immunomodulator like azathioprine, as this can reduce the likelihood of antibody formation.65  
  * **Specific Biologic Class Risks:**  
    * **Anti-TNF agents:** Rarely, they have been associated with the development or worsening of heart failure, neurological problems (like multiple sclerosis), a lupus-like syndrome, and new or worsening psoriasis. There is also a small, debated risk of lymphoma.60  
  * **Loss of Response:** Some individuals may initially respond well to a biologic, only to find its effectiveness wanes over time (secondary loss of response).70 This can be due to antibody development or other mechanisms.  
  * **Cost:** Biologic therapies are generally expensive.70  
  * **Patient Selection and Sequencing:** The choice of which biologic to use, and in what order if one fails, is a complex decision that depends on factors like disease severity, previous treatments, presence of EIMs, safety profile of the drug, patient preference (e.g., IV vs. injection), and coexisting conditions.40

The advent of biologic therapies marked a significant step towards more targeted immunomodulation in UC. However, they are not a universal solution. The potential for immunogenicity and the need for careful patient selection and sequencing of these agents are ongoing challenges. Research continues to focus on identifying biomarkers to predict response, optimizing dosing strategies, and developing new biologics with improved efficacy and safety profiles.

#### **5.2.5. Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators (Small Molecules)**

These medications represent a newer class of treatments for ulcerative colitis known as "small molecules." Unlike biologics, which are large protein-based drugs typically administered by injection or infusion, small molecules are chemically synthesized compounds that are usually taken orally (as pills).54 Their small size allows them to enter cells and modulate intracellular signaling pathways involved in inflammation. They generally have shorter half-lives than biologics and a lower risk of immunogenicity (the body developing antibodies against them).54

* **Janus Kinase (JAK) Inhibitors:**  
  * **Examples:**  
    * **Tofacitinib (Xeljanz):** Approved for moderate to severe UC.43  
    * **Upadacitinib (Rinvoq):** Also approved for moderate to severe UC.43  
    * **Filgotinib (Jyseleca):** Approved in Europe and Japan for UC, but not currently FDA-approved for UC in the US.43  
  * **Mechanism of Action:** JAK enzymes (JAK1, JAK2, JAK3, and TYK2) are critical components of intracellular signaling pathways for many cytokines (immune-signaling proteins) that drive inflammation in UC. When cytokines bind to their receptors on immune cells, JAK enzymes are activated, leading to a cascade of events that ultimately alters gene expression and promotes inflammation. JAK inhibitors work by blocking the activity of these JAK enzymes, thereby dampening the inflammatory response triggered by multiple cytokines simultaneously.54 Tofacitinib is considered a pan-JAK inhibitor (affecting multiple JAKs), while upadacitinib and filgotinib are more selective for JAK1, which is thought to potentially offer a more favorable side effect profile, though this is still being studied.81  
  * **Use and Efficacy:** JAK inhibitors are used to treat moderate to severe UC, often in individuals who have not responded to or cannot tolerate other treatments, including biologics.43 They are administered orally. Clinical trials have demonstrated their effectiveness in both inducing and maintaining remission. For tofacitinib, induction studies showed clinical remission rates around 33-48% (depending on dose) at 8 weeks, and maintenance studies showed remission rates of 34-40% at 52 weeks.54 Upadacitinib has also shown strong efficacy, with some induction trials reporting remission rates of around 20-33% at 8 weeks.80 In comparative network meta-analyses, upadacitinib frequently ranks as one of the most effective therapies for achieving various endpoints like clinical remission and endoscopic improvement in UC.53  
  * **Side Effects and FDA Warnings:** While offering the convenience of oral administration, JAK inhibitors have a distinct safety profile that requires careful consideration:  
    * **Common side effects:** Upper respiratory tract infections, headache, diarrhea, rash, and an increase in blood cholesterol levels (which needs monitoring).78  
    * **Serious Side Effects and FDA Boxed Warnings:**  
      * **Serious Infections:** There is an increased risk of developing serious bacterial, viral (especially herpes zoster/shingles – vaccination is often recommended for eligible patients before or during therapy), and fungal infections.43  
      * **Major Adverse Cardiovascular Events (MACE):** An increased risk of heart attack, stroke, and other serious heart-related problems has been identified, particularly in certain patient populations (e.g., older patients with existing cardiovascular risk factors, often noted in studies of rheumatoid arthritis patients).43  
      * **Thrombosis (Blood Clots):** An increased risk of blood clots in the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) has been observed.43  
      * **Malignancy:** There is a potential increased risk of certain cancers, including lymphoma and lung cancer. The FDA label includes warnings about this, though the absolute risk and its direct applicability from rheumatoid arthritis studies (where many of these risks were first highlighted) to IBD populations are still areas of ongoing research and discussion.43  
      * **Increased Mortality:** The FDA warning for tofacitinib, based on a post-marketing safety study in rheumatoid arthritis patients, noted an increased risk of death in patients treated with tofacitinib compared to those on TNF inhibitors, particularly at higher doses or in those with cardiovascular risk factors.43  
  * **Considerations:** Due to these safety concerns, JAK inhibitors are often reserved for patients who have failed or are intolerant to anti-TNF therapies.77 A thorough discussion of individual risk factors for these side effects is essential before starting treatment. They are generally not recommended for individuals who are pregnant or breastfeeding, or those with a history of blood clots or significant heart problems, without careful evaluation.80  
* **Sphingosine-1-Phosphate (S1P) Receptor Modulators:**  
  * **Examples:**  
    * **Ozanimod (Zeposia):** Approved for moderate to severe UC.43  
    * **Etrasimod (Velsipity):** Also approved for moderate to severe UC \[79 (Phase 3 trial protocol for etrasimod)\].  
  * **Mechanism of Action:** S1P receptors play a role in controlling the movement of lymphocytes (a type of white blood cell) out of lymph nodes and into the bloodstream. S1P receptor modulators bind to these receptors on lymphocytes, effectively trapping them within the lymph nodes. This reduces the number of circulating lymphocytes that can travel to the intestines and contribute to inflammation.54  
  * **Use and Efficacy:** These are oral medications used for treating moderate to severe UC.70 Clinical trials have demonstrated their efficacy in inducing and maintaining remission.  
  * **Side Effects and Considerations:**  
    * **Bradycardia (Slow Heart Rate) and Atrioventricular (AV) Conduction Delays:** These drugs can cause a temporary decrease in heart rate and may affect the heart's electrical conduction, particularly upon initiation of therapy. Therefore, cardiac monitoring (including an ECG) is typically required before starting treatment and during the initial dosing period. They may be contraindicated in patients with certain pre-existing heart conditions.77  
    * **Macular Edema:** A rare but potential side effect involving swelling in the macula of the eye, which can affect vision. An ophthalmologic examination may be recommended before starting treatment, especially for individuals with risk factors like diabetes.77  
    * **Increased Risk of Infections:** As they affect lymphocyte trafficking, there is an increased risk of infections. Screening for varicella-zoster virus (chickenpox/shingles) and vaccination if needed is advised.77  
    * **Liver Enzyme Elevation:** Liver function tests should be monitored.77  
    * **Hypertension:** Blood pressure should be monitored.  
  * **Considerations:** S1P receptor modulators offer another oral option with a novel mechanism of action. Their safety profile is generally considered favorable in terms of not causing broad immunosuppression to the same degree as some other agents, but they have specific cardiac and ophthalmologic monitoring requirements.

Small molecule drugs like JAK inhibitors and S1P receptor modulators have expanded the therapeutic armamentarium for UC, offering valuable oral alternatives, especially for patients who have not responded to or cannot tolerate biologic therapies. Their distinct mechanisms of action mean they can be effective even when biologics have failed. However, their unique safety profiles necessitate careful patient selection, thorough discussion of risks and benefits, and diligent monitoring for potential adverse events. The convenience of an oral pill must always be weighed against these specific considerations.

#### **5.2.6. Other Medicines for Symptom Management**

While the primary goal of UC treatment is to control the underlying inflammation, other medications may sometimes be used to manage specific symptoms. However, it is crucial that these are used under the guidance of a healthcare professional, as some can be harmful if used inappropriately, especially during active disease.

* **Antidiarrheal medicines:** For individuals experiencing severe diarrhea, medications like loperamide (Imodium A-D) might be considered.43 However, these should be used with extreme caution, particularly during an acute, severe flare of UC. Suppressing bowel motility in the presence of severe colonic inflammation can increase the risk of developing toxic megacolon, a life-threatening complication where the colon becomes massively dilated.43 Therefore, antidiarrheals should only be used after consultation with a doctor and generally avoided if there is active, significant inflammation.  
* **Pain relievers:** For mild pain, acetaminophen (Tylenol, paracetamol) is generally considered the safest option.43 Nonsteroidal anti-inflammatory drugs (NSAIDs)—such as ibuprofen (Advil, Motrin IB), naproxen sodium (Aleve), and diclofenac—should be **avoided** by individuals with ulcerative colitis.3 NSAIDs can irritate the gastrointestinal lining, potentially worsening UC symptoms, triggering flare-ups, and even increasing the severity of the disease.14  
* **Antispasmodics:** These medications may be prescribed to help relieve abdominal cramps by reducing muscle spasms in the gut.43  
* **Iron supplements:** If chronic intestinal bleeding leads to iron deficiency anemia, iron supplements will be necessary to replenish iron stores and help the body produce more red blood cells.17 Iron can be given orally or, if not well tolerated or in cases of severe deficiency, intravenously.

It is vital to reiterate that these symptomatic treatments do not address the root cause of UC, which is inflammation. Relying solely on them without effectively managing the underlying disease can mask a worsening condition or lead to complications. Always discuss the use of any over-the-counter or prescription medications for symptom relief with your gastroenterologist.

### **5.3. Surgical Options: When Is Surgery Needed?**

Surgery plays a critical role in the management of ulcerative colitis for a subset of patients. While many individuals can manage their condition with medication, surgery may become necessary or be the preferred option in certain circumstances.43 The most common reason for elective surgery is intractable disease, where medical therapy fails to adequately control symptoms or leads to unacceptable side effects, significantly impacting quality of life.43

Surgery is also indicated in emergency situations or for specific complications, including:

* **Life-threatening complications:**  
  * **Toxic megacolon:** A severe, acute dilation and inflammation of the colon that can lead to perforation if not treated promptly.1  
  * **Colon perforation:** A hole in the wall of the colon, which is a surgical emergency.1  
  * **Massive hemorrhage:** Severe, uncontrolled bleeding from the colon that cannot be stopped by other means.28  
* **Failure of medical therapy:** When symptoms persist despite optimal medical treatment, or when rescue therapies (like infliximab or cyclosporine) for acute severe colitis fail.50  
* **Corticosteroid dependence:** When an individual cannot discontinue corticosteroids without their symptoms flaring, leading to the risks of long-term steroid side effects.43  
* **Colorectal cancer or precancerous changes (dysplasia):** Ulcerative colitis increases the long-term risk of colorectal cancer. If cancer or high-grade dysplasia (abnormal, precancerous cells) is found during surveillance colonoscopies, surgical removal of the colon (colectomy) is typically recommended to prevent cancer development or treat existing cancer.29  
* **Growth retardation in children:** If UC severely impairs growth and development in children despite medical therapy, surgery may be considered.28

It's important to note that colectomy is considered a "cure" for ulcerative colitis because it removes the diseased organ (the colon and rectum) where the inflammation occurs.43 Approximately one-quarter to one-third of patients with UC may eventually require surgery.51

There are several main surgical approaches:

#### **5.3.1. Proctocolectomy with Ileoanal Anastomosis (IPAA / J-Pouch Surgery)**

This is currently the most common surgical procedure for ulcerative colitis when elective surgery is planned.88

* **Procedure:** The entire colon and rectum are removed (proctocolectomy). The surgeon then uses the end portion of the small intestine (the ileum) to create an internal pouch, most commonly shaped like a "J" (hence "J-pouch"). This pouch is then connected (anastomosed) to the anus.43 This procedure allows individuals to continue passing stool through the anus, maintaining continence and avoiding the need for a permanent external stoma (ostomy bag).43 IPAA surgery is often performed in two or three stages. A common approach involves removing the colon and rectum, creating the J-pouch, and creating a temporary ileostomy (where the small intestine is brought out to the skin of the abdomen to divert stool). This temporary ileostomy allows the newly created pouch and anastomosis to heal without being irritated by stool. After a healing period of several weeks or months, a second surgery is performed to close the temporary ileostomy and "connect" the J-pouch, allowing stool to pass into it and out through the anus.43  
* **Outcomes and Quality of Life:** J-pouch surgery generally has high long-term success rates, with some studies reporting around 95% stoma-free success in experienced surgical centers.90 Most individuals report a significant improvement in their quality of life after recovering from the surgery, as they are free from the symptoms of UC and do not require an external ostomy appliance.88 However, bowel function is different after J-pouch surgery. Individuals typically experience more frequent bowel movements (e.g., initially up to 10-12 times a day, settling to around 5-10 times a day over time) which are looser or more watery in consistency compared to before UC or with a healthy colon.87 Full recovery and adaptation to the J-pouch can take several months.91  
* **Potential Complications:**  
  * **Pouchitis:** This is the most common long-term complication, involving inflammation of the J-pouch itself. It can occur in up to 50% of patients, often within the first two years after surgery.90 Symptoms of pouchitis can mimic those of UC, including increased stool frequency, diarrhea, abdominal cramping, urgency, fever, dehydration, and sometimes joint pain.90 Most cases of acute pouchitis respond well to a course of antibiotics.90 However, some individuals may develop chronic or recurrent pouchitis that requires ongoing medical therapy or other interventions.90 Risk factors for developing pouchitis include having extraintestinal manifestations (especially PSC) before surgery, extensive colitis (pancolitis), and backwash ileitis.96  
  * **Anastomotic Stricture:** Narrowing at the site where the pouch is connected to the anus (the anastomosis) due to scar tissue formation. This can cause difficulty passing stool and may require dilation.90  
  * **Small Bowel Obstruction:** Blockage of the small intestine, often caused by adhesions (bands of scar tissue that can form after any abdominal surgery).88  
  * **Anastomotic Leak:** Leakage of intestinal contents from the site where the pouch is joined to the anus. This is a serious early complication that may require further surgery.91  
  * **Fistulas or Abscesses:** Abnormal connections (fistulas) or collections of pus (abscesses) can develop in the pelvic area.91  
  * **Fecal Incontinence or Leakage:** Some degree of difficulty controlling bowel movements, particularly at night or with gas, can occur in a minority of patients (around 10-20%).91  
  * **Sexual Dysfunction or Infertility:** Rarely, nerve damage during pelvic surgery can lead to sexual dysfunction in males. In females, pelvic adhesions or scar tissue around the ovaries and fallopian tubes may potentially impact fertility.93 Laparoscopic surgery may reduce the risk of female infertility compared to open surgery.91  
  * **Pouch Failure:** In a small percentage of cases (estimates range from 2% to 15%, with an overall prevalence around 6%), the J-pouch may fail due to persistent complications like chronic intractable pouchitis, fistulas, or severe dysfunction.90 Pouch failure typically necessitates surgical removal of the J-pouch and conversion to a permanent end ileostomy.90

#### **5.3.2. Proctocolectomy with End Ileostomy**

* **Procedure:** In this operation, the entire colon, rectum, and anus are removed (total proctocolectomy).50 The end of the small intestine (ileum) is then brought out through a surgically created opening (stoma) in the abdominal wall, usually on the right side. Stool passes from the ileum, through the stoma, and is collected in an external ostomy pouch (bag) that is worn over the stoma and adheres to the skin.43 This ileostomy is permanent.  
* **Indications:** This procedure may be chosen if IPAA (J-pouch) surgery is not technically feasible or advisable. Reasons might include poor anal sphincter muscle function (which would compromise continence with a J-pouch), the presence of cancer low in the rectum requiring wider removal, patient preference, older age, or if the individual is too ill or frail to undergo the more complex and lengthy J-pouch surgery.88 It is also the outcome if a J-pouch fails and needs to be removed.51  
* **Outcomes and Quality of Life:** Proctocolectomy with end ileostomy also cures the ulcerative colitis itself by removing all the diseased tissue.86 Many individuals with permanent ileostomies live full, active, and productive lives, including participating in sports, work, and travel.86 There is an adjustment period to living with and managing the stoma and ostomy appliance.85 Some individuals may experience "phantom rectum," a sensation of needing to have a bowel movement even though the rectum has been removed; this usually subsides over time.86  
* **Potential Complications:** Besides general surgical risks, specific complications related to an ileostomy can include:  
  * **Stoma-related issues:** Such as prolapse (stoma protrudes too far), retraction (stoma sinks below skin level), stenosis (narrowing of the stoma opening), skin irritation or breakdown around the stoma from appliance leakage or stool contact, and parastomal hernia (bowel protruding alongside the stoma).86  
  * **Blockage/Obstruction:** The small intestine can become blocked, sometimes due to food, adhesions, or stoma narrowing.86  
  * **Dehydration and Electrolyte Imbalance:** The colon normally absorbs a significant amount of water and electrolytes. With an ileostomy, stool output is more liquid and frequent, increasing the risk of dehydration and electrolyte disturbances if fluid and salt intake are not adequately managed.86  
  * **High Output Stoma:** Some individuals may experience very high volumes of stool output from the ileostomy, requiring specific dietary and medical management.

#### **5.3.3. Continent Ileostomy (e.g., Kock Pouch)**

* **Procedure:** This is a less commonly performed alternative to a conventional end ileostomy that also avoids an external bag.43 An internal reservoir (pouch) is constructed from the ileum, similar to a J-pouch, but it is situated inside the abdomen. A special nipple valve is created at the outlet of the pouch, which leads to a small, flush stoma on the abdominal wall. This valve is designed to keep the pouch continent (preventing leakage of stool). The individual drains the pouch several times a day by inserting a thin tube (catheter) through the stoma and into the valve.43 Examples include the Kock pouch, Barnett continent intestinal reservoir (BCIR), and T-pouch.  
* **Indications:** This may be an option for individuals who cannot have or do not want a J-pouch (perhaps due to anal sphincter issues or previous J-pouch failure) and who also wish to avoid a conventional ileostomy with an external bag.98  
* **Outcomes and Quality of Life:** Studies suggest that patients with a continent ileostomy can achieve a good quality of life and high levels of satisfaction.98 However, this procedure is associated with a high rate of reoperation, often ranging from 20% to 65%, primarily due to problems with the valve mechanism (e.g., slipping, fistulization, difficulty intubating).98 Other complications can include fistulas (abnormal connections) and stomal stenosis (narrowing).98 Despite these challenges, long-term pouch retention can be high.98  
* **Considerations:** Continent ileostomy is a technically demanding operation and is performed at specialized centers. The need for frequent reoperations is a significant factor to consider.

The decision regarding which surgical procedure is most appropriate is highly individualized and should be made after a thorough discussion between the patient and their colorectal surgeon. This discussion should cover the specifics of the patient's disease, their overall health, anal sphincter function, personal preferences, lifestyle considerations, and a detailed understanding of the potential benefits, risks, and long-term implications of each option. While J-pouch surgery is often preferred for its aim to maintain near-normal bowel function without a permanent stoma, it is not without its own set of potential long-term challenges, such as pouchitis or, rarely, pouch failure.90 For some individuals, a well-functioning permanent ileostomy may ultimately provide a better and more predictable quality of life than a J-pouch with persistent complications.90

In emergency situations, such as toxic megacolon or perforation, the primary goal of surgery is life-saving. In these critical scenarios, surgeons often perform a subtotal colectomy (removal of most of the colon) with the creation of an end ileostomy and closure of the remaining rectal stump (Hartmann procedure) or creation of a mucous fistula.85 This is a less extensive and quicker operation than a full proctocolectomy with J-pouch construction, making it safer for critically ill patients.85 This approach allows the patient to recover from the acute illness, discontinue immunosuppressive medications, and improve their nutritional status. A more definitive reconstructive surgery, such as J-pouch creation or completion proctectomy, can then be planned as a second-stage procedure when the patient is in a much better state of health.85 This staged approach prioritizes patient safety and optimizes the chances of a successful long-term outcome.

## **6\. Diet and Nutrition: Eating Well with Ulcerative Colitis**

Diet and nutrition play a significant supportive role in managing ulcerative colitis, although it's crucial to understand that diet does not cause UC, nor can it cure it.1 However, what an individual eats can affect their symptoms, nutritional status, and overall well-being, especially during flare-ups and periods of remission.99 Dietary strategies aim to reduce symptoms, replace lost nutrients, promote healing, and maintain good nutrition. Individual responses to foods can vary greatly, so a personalized approach, often with the guidance of a registered dietitian experienced in IBD, is essential.99

### **6.1. General Dietary Recommendations: Flare-Ups vs. Remission**

Dietary needs and tolerances can change significantly depending on whether UC is active (flare-up) or inactive (remission).

* During a Flare-Up:  
  When the colon is actively inflamed and ulcerated, the primary goal is to choose foods that are gentle on the digestive system, minimize irritation, and reduce symptoms like diarrhea and pain.99  
  * **Low-Fiber/Low-Residue Diet:** Many healthcare providers recommend a temporary low-fiber or low-residue diet during flares.99 "Residue" refers to undigested food parts, including fiber, that can increase stool bulk and frequency. Limiting high-fiber foods such as raw fruits and vegetables (especially those with skins and seeds), whole grains, nuts, and seeds can help reduce bowel movements and discomfort.99 Cooked, peeled, and seedless fruits and vegetables (e.g., bananas, cantaloupe, applesauce, well-cooked carrots, squash, green beans) and refined grains (e.g., white rice, white bread, white pasta) are often better tolerated.100  
  * **Soft, Bland Foods:** Opting for soft, bland, and easy-to-digest foods can be helpful.103  
  * **Adequate Protein:** Protein needs may increase during active inflammation to support healing.21 Lean proteins like well-cooked poultry, fish, eggs, and tofu are good choices.100  
  * **Hydration:** Frequent diarrhea can lead to dehydration and electrolyte loss. It's crucial to drink plenty of fluids, such as water, broth, diluted fruit juices (pulp-free), or oral rehydration solutions.99  
  * **Small, Frequent Meals:** Eating smaller meals more frequently throughout the day, rather than three large ones, can be easier on the digestive system.99  
  * **Avoid Known Triggers:** Individuals should avoid any foods they have personally identified as worsening their symptoms. Common culprits during flares include spicy foods, high-fat foods, caffeine, alcohol, and sometimes dairy products if lactose intolerance is an issue.99  
* During Remission:  
  When UC is in remission and symptoms are absent or minimal, the dietary focus shifts towards maintaining a balanced, nutrient-rich diet to support overall health and prevent deficiencies.99  
  * **Gradual Reintroduction of Foods:** As inflammation subsides, individuals can gradually reintroduce a wider variety of foods, including fiber, back into their diet.99 It's often recommended to add only one or two new foods per week in small amounts to monitor for any adverse reactions.102  
  * **Balanced Diet:** Aim for a diet rich in fruits, vegetables (cooked or raw as tolerated), lean proteins, and whole grains (if tolerated).99 A Mediterranean-style diet, emphasizing plants, healthy fats like olive oil, and fish, is often suggested for its anti-inflammatory properties.103  
  * **Fiber:** While limited during flares, fiber is important for long-term gut health during remission. Soluble fiber (found in oats, bananas, peeled apples) can help absorb water and form softer stools, while insoluble fiber (found in whole grains, raw vegetables, nuts, seeds) adds bulk. Individual tolerance to different types and amounts of fiber varies.99  
  * **Healthy Fats:** Include sources of monounsaturated fats (olive oil, avocados) and omega-3 fatty acids (fatty fish like salmon, flaxseed, walnuts), which may have anti-inflammatory benefits.99 Limit trans fats and excessive saturated fats from red and processed meats, which may be pro-inflammatory.99  
  * **Protein:** Continue to include adequate protein from sources like fish, poultry, eggs, legumes (if tolerated), and tofu.99  
  * **Hydration:** Maintain good fluid intake.99  
  * **Identify and Manage Individual Triggers:** Even in remission, some individuals may find that specific foods can still cause mild symptoms. Keeping a food and symptom journal can help identify these personal triggers so they can be managed or avoided.99 However, it is important not to overly restrict the diet without professional guidance, as this can lead to nutrient deficiencies.105

### **6.2. Foods to Potentially Eat and Avoid**

While individual tolerances vary greatly, some foods are commonly reported as being better tolerated or potentially problematic for people with UC.

* **Foods Often Better Tolerated (Especially During Flares or for Sensitive Individuals):**  
  * **Lean Proteins:** Well-cooked chicken, turkey, fish (especially fatty fish like salmon for omega-3s), eggs, tofu.100  
  * **Refined Grains:** White rice, white pasta, white bread (e.g., sourdough), oatmeal, cream of wheat, rice-based cereals.100  
  * **Low-Fiber Fruits:** Bananas, cantaloupe, honeydew melon, watermelon, peeled apples or applesauce, canned fruits in juice (avoiding pineapple for some), fruit juices diluted with water (pulp-free).100  
  * **Well-Cooked, Peeled, Seedless Vegetables:** Potatoes (white, red, yellow without skin), sweet potatoes (skin removed, in moderation), carrots, squash (e.g., zucchini, summer squash without skins/seeds), green beans, asparagus tips, strained vegetable juice, pureed tomato sauce.100  
  * **Dairy/Alternatives (if tolerated):** Lactose-free milk, yogurt with live active cultures (plain), kefir, hard cheeses (cheddar, Swiss, parmesan may have less lactose). Fortified non-dairy milks (almond, rice, soy – though soy may cause gas for some).99  
  * **Fats:** Olive oil, canola oil, smooth nut butters (peanut, almond) in moderation.99  
  * **Probiotic-rich foods:** Yogurt, kefir, pickles, miso, sauerkraut, tempeh (tolerance varies).100  
* **Foods That May Worsen Symptoms or Are Commonly Avoided (Especially During Flares):**  
  * **High-Fiber Foods:**  
    * **Insoluble fiber:** Raw vegetables (especially cruciferous ones like broccoli, cauliflower, cabbage, Brussels sprouts), fruit skins and seeds, whole nuts, whole seeds (sunflower, pumpkin), popcorn, whole grains (whole wheat, brown rice, quinoa, bran).99  
    * Legumes (beans, lentils, peas).99  
  * **Fatty, Greasy, or Fried Foods:** High-fat meats (red meat, processed meats like bacon, sausage, deli meats), cream, butter, margarine, fried foods.99 These can increase gas and diarrhea due to incomplete fat absorption.  
  * **Spicy Foods:** Hot peppers, hot sauces, and other spicy seasonings can irritate the digestive tract.99  
  * **Dairy Products (for those with lactose intolerance):** Cow's milk, ice cream, soft cheeses, cream. Lactose intolerance is common in IBD and can cause gas, bloating, pain, and diarrhea.99  
  * **Sugary Foods and Drinks:** Candies, pastries, sodas, sweetened beverages, some fruit juices (especially those high in fructose or sorbitol), sugar alcohols (sorbitol, mannitol, xylitol found in sugar-free products) can worsen diarrhea.99  
  * **Alcohol and Caffeine:** Can irritate the gut and stimulate bowel movements.99  
  * **Gluten:** Some individuals with IBD report sensitivity to gluten (a protein in wheat, barley, rye) and find that avoiding gluten-containing foods improves symptoms like bloating and diarrhea, though celiac disease needs to be ruled out.100  
  * **Certain Vegetables and Fruits:** Onions, garlic, artichokes, asparagus (stalks), apples, peaches, pears, prunes (often high in FODMAPs).100 Corn and corn-based products.99  
  * **Processed Foods with Additives:** Some research suggests certain food additives (e.g., emulsifiers like carboxymethylcellulose, polysorbate-80; artificial sweeteners) may play a role in inflammation, though more research is needed.105

It is essential to remember that these are general guidelines. The best approach is to identify personal trigger foods through careful observation, possibly with the help of a food diary and a dietitian.99 The goal is to maintain the most varied and nutritious diet possible while managing symptoms.

### **6.3. Specific Diets: Low-FODMAP, SCD, IBD-AID, and Others**

Several specific dietary approaches have been proposed or studied for managing symptoms in IBD, including UC. It's important to note that while some of these diets may help alleviate symptoms for certain individuals, they are generally not considered cures for UC and should be undertaken with caution and often under professional supervision to avoid nutritional deficiencies.

* **Low-FODMAP Diet:**  
  * **Concept:** FODMAPs are Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols – types of short-chain carbohydrates that can be poorly absorbed in the small intestine. When they reach the large intestine, they are fermented by gut bacteria, producing gas, and can also draw water into the bowel, leading to symptoms like bloating, pain, gas, and diarrhea.100  
  * **Approach:** The diet involves an initial elimination phase (typically 4-6 weeks) where all high-FODMAP foods are avoided, followed by a structured reintroduction phase to identify which specific FODMAPs trigger symptoms and in what amounts.107  
  * **Efficacy in UC:** While the Low-FODMAP diet was originally developed for Irritable Bowel Syndrome (IBS), it has shown promise in reducing IBS-like functional gut symptoms (such as bloating, pain, diarrhea) that can persist in UC patients even when their inflammation is in remission.107 It is **not** designed to reduce the underlying inflammation of UC itself.107  
  * **Foods:** High-FODMAP foods to avoid/limit during elimination include certain fruits (apples, pears, mangoes, watermelon), vegetables (onions, garlic, cauliflower, asparagus), dairy products containing lactose, wheat and rye products, legumes, and certain sweeteners (honey, high-fructose corn syrup, sugar alcohols).100 Low-FODMAP alternatives are consumed instead.  
  * **Considerations:** This diet is intended to be temporary and should ideally be guided by a dietitian experienced in its use to ensure nutritional adequacy and proper reintroduction of foods.107 It is not a replacement for UC medications.107  
* **Specific Carbohydrate Diet (SCD):**  
  * **Concept:** The theory behind SCD is that complex carbohydrates are poorly digested and feed harmful bacteria in the gut, leading to inflammation and damage to the intestinal wall. The diet aims to "starve out" these bacteria by allowing only specific, easily digestible simple carbohydrates (monosaccharides).100  
  * **Approach:** SCD is highly restrictive. It eliminates all grains (wheat, rice, corn, oats), starchy vegetables (potatoes, sweet potatoes), most dairy products (except for specific hard cheeses and homemade yogurt fermented for at least 24 hours), and all processed foods and sugars (except honey).100 It emphasizes meats, fish, eggs, most fruits and non-starchy vegetables, nuts, and specific legumes.  
  * **Efficacy in UC:** Current nutrition guidelines from major IBD organizations generally do not recommend the SCD for inducing or maintaining remission in UC due to a lack of robust, high-quality research supporting its use for this purpose.109 While some anecdotal reports and small studies suggest potential benefits for some individuals 110, larger controlled trials are needed. One study comparing SCD to a Mediterranean diet in Crohn's disease patients found no significant difference in symptom reduction or inflammatory markers.109  
  * **Considerations:** SCD is very challenging to follow due to its restrictive nature, potential for nutritional deficiencies, cost, and time commitment for food preparation.109 Professional guidance from a dietitian is crucial if considering this diet.  
* **IBD Anti-Inflammatory Diet (IBD-AID):**  
  * **Concept:** Developed to help restore balance in the gut microbiome and reduce inflammation. It incorporates features of the SCD but also emphasizes the inclusion of prebiotic and probiotic foods.103  
  * **Approach:** Restricts certain carbohydrates (lactose, refined/processed complex carbohydrates) and includes foods rich in prebiotics (which feed beneficial gut bacteria, e.g., oats, bananas, onions – though some of these may be high FODMAP and need careful introduction) and probiotics (live beneficial bacteria, e.g., yogurt, kefir, miso, sauerkraut). It progresses through phases, starting with softer, pureed foods.103  
  * **Efficacy in UC:** This is a newer dietary concept, and while based on sound principles regarding the microbiome and inflammation, more research is needed to establish its specific efficacy in UC.  
* **Mediterranean Diet:**  
  * **Concept:** Emphasizes whole, unprocessed foods, including plenty of fruits, vegetables, whole grains (if tolerated), legumes (if tolerated), nuts, seeds, lean proteins (especially fish and poultry), and healthy fats (primarily olive oil). Red meat and processed foods are limited.103  
  * **Efficacy in UC:** Often recommended for its general anti-inflammatory properties and overall health benefits.103 The American Gastroenterological Association (AGA) suggests that a Mediterranean diet rich in fruits, vegetables, monounsaturated fats, complex carbs, lean proteins, and low in ultra-processed foods and added sugar may benefit patients with IBD.106 Adaptations, such as cooking or pureeing fruits and vegetables, may be needed for those with strictures or during flares.103  
* **Plant-Based Diets (Vegetarian, Vegan):**  
  * **Concept:** Focus on foods primarily from plants. May help with inflammation due to high intake of fiber and phytonutrients from fruits and vegetables.103  
  * **Considerations:** Careful planning is needed to ensure adequate intake of all essential nutrients, particularly vitamin B12 (if no animal products are consumed), iron, calcium, and protein. May be challenging to tolerate during active UC flares due to high fiber content unless modified.103  
* **Exclusive Enteral Nutrition (EEN):**  
  * **Concept:** Involves consuming only a nutritionally complete liquid formula for a defined period, providing bowel rest.  
  * **Efficacy in UC:** While EEN is a well-established first-line therapy for inducing remission in pediatric Crohn's disease and can be used in adults with CD 106, its role in ulcerative colitis is less clear and not as strongly supported by evidence or guidelines for primary therapy.21 It might be considered in specific situations, such as severe malnutrition or pre-operatively, but is not a standard induction therapy for UC flares in the same way it is for Crohn's disease. Partial enteral nutrition (PEN), where formula supplements a portion of the diet, might be used to improve nutritional status.108

No single diet has been proven to consistently prevent or control UC for everyone.108 The most effective dietary strategy is often highly individualized, focusing on nutrient adequacy, symptom management, and personal tolerance, ideally developed in collaboration with a doctor and a registered dietitian specializing in IBD.99

### **6.4. Nutritional Supplements: When Are They Needed?**

Individuals with ulcerative colitis are at an increased risk of developing nutritional deficiencies due to several factors, including reduced food intake (due to pain, nausea, or restrictive diets), malabsorption of nutrients (caused by inflammation and diarrhea), increased nutrient losses (from bleeding or diarrhea), and medication side effects (e.g., corticosteroids affecting calcium and vitamin D metabolism).17 Therefore, nutritional supplements may be necessary to prevent or correct these deficiencies and support overall health. Regular screening for common deficiencies is often recommended.21

Common deficiencies and relevant supplements include:

* **Iron:** Iron deficiency anemia is very common in UC (affecting 36-76% of IBD patients) due to chronic blood loss from intestinal ulcers and sometimes impaired iron absorption.17 Symptoms include fatigue, weakness, and shortness of breath. Iron supplements (oral or intravenous if oral iron is not tolerated or absorbed well, or in severe cases) are often needed.17 It's important to have iron levels tested before taking supplements, as excess iron can be harmful.84  
* **Vitamin B12:** This vitamin is crucial for nerve function and red blood cell formation. It is primarily absorbed in the terminal ileum (the last part of the small intestine). While UC primarily affects the colon, severe inflammation extending to the very end of the small intestine (backwash ileitis) or previous surgeries involving the ileum could impair B12 absorption.17 Supplementation (oral, sublingual, or injections) may be required.  
* **Vitamin D:** Deficiencies are common in IBD.17 Vitamin D is essential for calcium absorption and bone health, and it may also play a role in immune regulation and controlling intestinal inflammation.21 Corticosteroid use further increases the need for vitamin D. Supplementation is often recommended, typically 800 IU per day or higher based on blood levels.17  
* **Calcium:** Important for bone health, especially crucial if taking corticosteroids, which can weaken bones and lead to osteoporosis.17 Calcium is best absorbed when taken with vitamin D.  
* **Folic Acid (Folate):** This B-vitamin is important for cell production. Some UC medications, like sulfasalazine and methotrexate, can interfere with its absorption or metabolism, necessitating supplementation.21 It's also vital for women of childbearing age to prevent neural tube defects in pregnancy.  
* **Vitamins A, E, and K (Fat-Soluble Vitamins):** Bowel inflammation can sometimes affect the absorption of fats, and consequently, these fat-soluble vitamins.17 Deficiencies can impact vision (Vitamin A), antioxidant functions (Vitamin E), and blood clotting (Vitamin K).  
* **Zinc:** This mineral is important for immune function and wound healing. Severe or chronic diarrhea can lead to zinc losses and deficiency.17 Symptoms of deficiency include rash, impaired taste/smell, and poor wound healing.  
* **Probiotics:** These are live "good" bacteria that may help restore a healthier balance to the gut microbiome.17 Some evidence suggests that certain probiotic formulations (like VSL\#3, now available as Visbiome or De Simone Formulation in different regions) may help induce or maintain remission in some individuals with UC, or help prevent pouchitis after J-pouch surgery.17 A 2023 meta-analysis suggested probiotic therapy may be effective in inhibiting UC recurrence in patients in remission and may increase remission rates in active UC, though caution is needed in interpreting efficacy for active disease.18 The specific strains and dosages likely matter, and more research is ongoing. It's best to discuss with a doctor before taking probiotics.17  
* **Omega-3 Fatty Acids:** Found in fish oil, these fatty acids have anti-inflammatory properties, and it was hypothesized they might benefit UC.17 However, systematic reviews and meta-analyses of studies using non-enteric coated fish oil for maintaining remission in UC have generally found no significant benefit compared to placebo.112 Further studies with different formulations (e.g., enteric-coated to allow release further down the intestine) might be warranted, but currently, they are not a proven therapy for UC maintenance.112

It is always recommended to discuss any vitamin or mineral supplementation with a healthcare provider or registered dietitian. They can assess individual needs based on blood tests, symptoms, diet, and medications, and recommend appropriate types and dosages of supplements to avoid potential toxicity or interactions.17 Checking supplement labels for potential irritants like lactose or sugar alcohols is also advisable.84

## **7\. Living with Ulcerative Colitis: Lifestyle Adjustments and Self-Care**

Managing ulcerative colitis effectively extends beyond medical treatments and dietary changes. Lifestyle adjustments and self-care strategies play a crucial role in coping with the condition, reducing symptom frequency and severity, and enhancing overall quality of life.114

### **7.1. Stress Management Techniques**

While stress is not a direct cause of ulcerative colitis, it is widely recognized as a significant factor that can exacerbate symptoms and trigger flare-ups.1 The unpredictable nature of UC, coupled with its often-debilitating symptoms, can itself be a source of considerable stress and anxiety, potentially creating a vicious cycle.1 Therefore, incorporating effective stress management techniques into daily life is highly beneficial.

Recommended strategies include:

* **Relaxation and Breathing Exercises:** Techniques such as deep diaphragmatic breathing, progressive muscle relaxation, and guided imagery can help calm the nervous system, reduce tension, and promote a sense of well-being.1  
* **Meditation and Mindfulness:** Regular meditation practice, including mindfulness meditation, can help individuals become more aware of their thoughts and feelings without judgment, reduce anxiety, and improve their ability to cope with stress and pain.114 Apps and guided recordings can be useful tools for learning these practices.117  
* **Yoga and Tai Chi:** These mind-body practices combine gentle movements, stretching, breathing exercises, and meditation, promoting relaxation, balance, muscle strength, and joint flexibility.114 Studies have shown yoga can improve quality of life and potentially reduce disease activity in IBD patients.119  
* **Regular Physical Exercise:** As detailed below, exercise is a powerful stress reliever and mood booster.1  
* **Engaging in Hobbies and Enjoyable Activities:** Making time for activities that bring joy and relaxation, such as reading, listening to music, spending time in nature, or pursuing creative interests, can help divert focus from illness and reduce stress.114  
* **Adequate Sleep:** Poor sleep can worsen stress and impact overall health. Practicing good sleep hygiene is important (discussed in section 7.3).  
* **Seeking Social Support:** Talking about feelings and experiences with trusted friends, family members, or support groups can alleviate feelings of isolation and provide emotional comfort \[114, S\_

#### **Works cited**

1. Ulcerative colitis \- Symptoms and causes \- Mayo Clinic, accessed on May 27, 2025, [https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326](https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326)  
2. Ulcerative Colitis \- NIDDK, accessed on May 27, 2025, [https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis](https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis)  
3. Inflammatory bowel disease (IBD) \- Symptoms and causes \- Mayo Clinic, accessed on May 27, 2025, [https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315](https://www.mayoclinic.org/diseases-conditions/inflammatory-bowel-disease/symptoms-causes/syc-20353315)  
4. Overview of Ulcerative Colitis | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/overview](https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/overview)  
5. Ulcerative colitis \- symptoms, causes and diagnosis \- Healthdirect, accessed on May 27, 2025, [https://www.healthdirect.gov.au/ulcerative-colitis](https://www.healthdirect.gov.au/ulcerative-colitis)  
6. Types of Ulcerative Colitis \- WebMD, accessed on May 27, 2025, [https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-types](https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-types)  
7. Colitis: Ulcerative, Ischemic, Microscopic and More \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/colitis](https://www.healthline.com/health/colitis)  
8. www.darmzentrum-bern.ch, accessed on May 27, 2025, [https://www.darmzentrum-bern.ch/fileadmin/darmzentrum/Education/Bible\_Class/2023/IBD/ECCO\_Guidelines\_Therapeutics\_UC\_2022.pdf](https://www.darmzentrum-bern.ch/fileadmin/darmzentrum/Education/Bible_Class/2023/IBD/ECCO_Guidelines_Therapeutics_UC_2022.pdf)  
9. Ulcerative Colitis: Prognosis and Life Expectancy, accessed on May 27, 2025, [https://resources.healthgrades.com/right-care/ulcerative-colitis/ulcerative-colitis-prognosis-and-life-expectancy](https://resources.healthgrades.com/right-care/ulcerative-colitis/ulcerative-colitis-prognosis-and-life-expectancy)  
10. Ulcerative colitis \- Genetics \- MedlinePlus, accessed on May 27, 2025, [https://medlineplus.gov/genetics/condition/ulcerative-colitis/](https://medlineplus.gov/genetics/condition/ulcerative-colitis/)  
11. Ulcerative Colitis and Genetics: Is It Hereditary? \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/is-ulcerative-colitis-hereditary](https://www.healthline.com/health/is-ulcerative-colitis-hereditary)  
12. Symptoms & Causes of Ulcerative Colitis \- NIDDK, accessed on May 27, 2025, [https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/symptoms-causes](https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/symptoms-causes)  
13. Ulcerative colitis \- Causes \- NHS, accessed on May 27, 2025, [https://www.nhs.uk/conditions/ulcerative-colitis/causes/](https://www.nhs.uk/conditions/ulcerative-colitis/causes/)  
14. Environmental factors and ulcerative colitis: Causes, risks, and more \- Medical News Today, accessed on May 27, 2025, [https://www.medicalnewstoday.com/articles/environmental-risk-factors-for-ulcerative-colitis](https://www.medicalnewstoday.com/articles/environmental-risk-factors-for-ulcerative-colitis)  
15. Research progress on the carcinogenesis mechanism of inflammation in ulcerative colitis: a narrative review \- Annals of Palliative Medicine, accessed on May 27, 2025, [https://apm.amegroups.org/article/view/83988/html](https://apm.amegroups.org/article/view/83988/html)  
16. The mechanism of traditional medicine in alleviating ulcerative colitis: regulating intestinal barrier function \- Frontiers, accessed on May 27, 2025, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1228969/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1228969/full)  
17. Recommended Vitamins and Supplements for Ulcerative Colitis, accessed on May 27, 2025, [https://resources.healthgrades.com/right-care/ulcerative-colitis/recommended-vitamins-and-supplements-for-ulcerative-colitis](https://resources.healthgrades.com/right-care/ulcerative-colitis/recommended-vitamins-and-supplements-for-ulcerative-colitis)  
18. Additive efficacy and safety of probiotics in the treatment of ulcerative colitis: a systematic review and meta-analysis \- PubMed, accessed on May 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/38446227/](https://pubmed.ncbi.nlm.nih.gov/38446227/)  
19. Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022 \- Frontiers, accessed on May 27, 2025, [https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1211271/full](https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2023.1211271/full)  
20. The Impact of Microbiome Interventions on the Progression and Severity of Inflammatory Bowel Disease \- Semantic Scholar, accessed on May 27, 2025, [https://pdfs.semanticscholar.org/160f/4fa4ac6e3293c3379c19e690cfc60df3ec4d.pdf](https://pdfs.semanticscholar.org/160f/4fa4ac6e3293c3379c19e690cfc60df3ec4d.pdf)  
21. ESPEN launches an updated guideline on nutrition in IBD, accessed on May 27, 2025, [https://www.nutritionaltherapyforibd.org/news/espen-launches-an-updated-guideline-on-nutrition-in-ibd](https://www.nutritionaltherapyforibd.org/news/espen-launches-an-updated-guideline-on-nutrition-in-ibd)  
22. How Diet Impacts IBD \- Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/how-diet-impacts-ibd](https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/how-diet-impacts-ibd)  
23. Smoking or vaping and Crohn's Disease, Ulcerative Colitis or Microscopic Colitis (IBD), accessed on May 27, 2025, [https://crohnsandcolitis.org.uk/smoking](https://crohnsandcolitis.org.uk/smoking)  
24. Ulcerative Colitis and Smoking: What You Should Know \- HealthCentral, accessed on May 27, 2025, [https://www.healthcentral.com/condition/ulcerative-colitis/ulcerative-colitis-and-smoking-the-surprising-link](https://www.healthcentral.com/condition/ulcerative-colitis/ulcerative-colitis-and-smoking-the-surprising-link)  
25. Signs and Symptoms of Ulcerative Colitis | Crohn's & Colitis ..., accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/symptoms](https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/symptoms)  
26. Ulcerative Colitis: Practice Essentials, Background, Anatomy \- Medscape Reference, accessed on May 27, 2025, [https://emedicine.medscape.com/article/183084-overview](https://emedicine.medscape.com/article/183084-overview)  
27. Blood Tests \- IBD Journey \- Getting Diagnosed \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diagnosis-and-Testing/Blood-Tests](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diagnosis-and-Testing/Blood-Tests)  
28. Ulcerative Colitis \- Gastrointestinal Disorders \- Merck Manual ..., accessed on May 27, 2025, [https://www.merckmanuals.com/professional/gastrointestinal-disorders/inflammatory-bowel-disease-ibd/ulcerative-colitis](https://www.merckmanuals.com/professional/gastrointestinal-disorders/inflammatory-bowel-disease-ibd/ulcerative-colitis)  
29. Ulcerative Colitis Complications and Prognosis \- Consensus: AI Search Engine for Research, accessed on May 27, 2025, [https://consensus.app/home/blog/ulcerative-colitis-complications-and-prognosis/](https://consensus.app/home/blog/ulcerative-colitis-complications-and-prognosis/)  
30. Ulcerative Colitis Extraintestinal Symptoms, Treatment, and More \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/ulcerative-colitis-extraintestinal-symptoms](https://www.healthline.com/health/ulcerative-colitis/ulcerative-colitis-extraintestinal-symptoms)  
31. (PDF) Extraintestinal Manifestations Of Ulcerative Colitis In Saudi Arabia: Systematic Review, accessed on May 27, 2025, [https://www.researchgate.net/publication/377200518\_Extraintestinal\_Manifestations\_Of\_Ulcerative\_Colitis\_In\_Saudi\_Arabia\_Systematic\_Review](https://www.researchgate.net/publication/377200518_Extraintestinal_Manifestations_Of_Ulcerative_Colitis_In_Saudi_Arabia_Systematic_Review)  
32. Ulcerative Colitis Pathology: Overview, Epidemiology, Etiology \- Medscape Reference, accessed on May 27, 2025, [https://emedicine.medscape.com/article/2005396-overview](https://emedicine.medscape.com/article/2005396-overview)  
33. 10 Skin Rashes Caused by Ulcerative Colitis \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis-skin-rash](https://www.healthline.com/health/ulcerative-colitis-skin-rash)  
34. Multiple eruptive ulcers in a patient with quiescent ulcerative colitis \- The BMJ, accessed on May 27, 2025, [https://www.bmj.com/content/364/bmj.l847](https://www.bmj.com/content/364/bmj.l847)  
35. Primary Sclerosing Cholangitis \- StatPearls \- NCBI Bookshelf, accessed on May 27, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK537181/](https://www.ncbi.nlm.nih.gov/books/NBK537181/)  
36. Primary sclerosing cholangitis \- Wikipedia, accessed on May 27, 2025, [https://en.wikipedia.org/wiki/Primary\_sclerosing\_cholangitis](https://en.wikipedia.org/wiki/Primary_sclerosing_cholangitis)  
37. The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8435245/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8435245/)  
38. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3729869/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3729869/)  
39. Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and meta-analysis \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6204254/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6204254/)  
40. A practical approach to positioning therapies in ulcerative colitis \- Oxford Academic, accessed on May 27, 2025, [https://academic.oup.com/jcag/article/8/Supplement\_2/S6/8029078](https://academic.oup.com/jcag/article/8/Supplement_2/S6/8029078)  
41. Ulcerative colitis \- Diagnosis \- NHS, accessed on May 27, 2025, [https://www.nhs.uk/conditions/ulcerative-colitis/diagnosis/](https://www.nhs.uk/conditions/ulcerative-colitis/diagnosis/)  
42. Diagnosis of Ulcerative Colitis \- NIDDK, accessed on May 27, 2025, [https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/diagnosis](https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/diagnosis)  
43. Ulcerative colitis \- Diagnosis and treatment \- Mayo Clinic, accessed on May 27, 2025, [https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/diagnosis-treatment/drc-20353331](https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/diagnosis-treatment/drc-20353331)  
44. Ulcerative Colitis Diagnosis and Testing: How It Works \- Verywell Health, accessed on May 27, 2025, [https://www.verywellhealth.com/ulcerative-colitis-diagnosis-8425344](https://www.verywellhealth.com/ulcerative-colitis-diagnosis-8425344)  
45. Diagnosing Inflammatory Bowel Disease \- NYU Langone Health, accessed on May 27, 2025, [https://nyulangone.org/conditions/inflammatory-bowel-disease/diagnosis](https://nyulangone.org/conditions/inflammatory-bowel-disease/diagnosis)  
46. Ulcerative Colitis Diagnosis and Testing | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/diagnosis-testing](https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/diagnosis-testing)  
47. Ulcerative Colitis Diagnosis \- Stanford Health Care, accessed on May 27, 2025, [https://stanfordhealthcare.org/medical-conditions/digestion-and-metabolic-health/ulcerative-colitis/diagnosis.html](https://stanfordhealthcare.org/medical-conditions/digestion-and-metabolic-health/ulcerative-colitis/diagnosis.html)  
48. Ulcerative Colitis Workup: Approach Considerations, Serologic Markers, Other Laboratory Studies \- Medscape Reference, accessed on May 27, 2025, [https://emedicine.medscape.com/article/183084-workup](https://emedicine.medscape.com/article/183084-workup)  
49. Stool Tests \- IBD Journey \- Getting Diagnosed \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diagnosis-and-Testing/Stool-Tests](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diagnosis-and-Testing/Stool-Tests)  
50. Treatment for Ulcerative Colitis \- NIDDK, accessed on May 27, 2025, [https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/treatment](https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis/treatment)  
51. Ulcerative Colitis Treatment Options | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/treatment-options](https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-ulcerative-colitis/treatment-options)  
52. IBD TREATMENTS \- European Crohn's and Colitis Organisation, accessed on May 27, 2025, [https://www.ecco-ibd.eu/images/1\_About\_ECCO/1\_8\_ECCO/IBDTreatments.pdf](https://www.ecco-ibd.eu/images/1_About_ECCO/1_8_ECCO/IBDTreatments.pdf)  
53. Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis \- Frontiers, accessed on May 27, 2025, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1481678/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1481678/full)  
54. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7211304/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7211304/)  
55. Ulcerative Colitis: What to Expect Over the Long Term \- WebMD, accessed on May 27, 2025, [https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/features/long-haul-expectations-uc](https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/features/long-haul-expectations-uc)  
56. Aminosalicylates: Types and Side-Effects \- Patient.info, accessed on May 27, 2025, [https://patient.info/digestive-health/inflammatory-bowel-disease/aminosalicylates](https://patient.info/digestive-health/inflammatory-bowel-disease/aminosalicylates)  
57. Mesalamine (USAN) \- StatPearls \- NCBI Bookshelf, accessed on May 27, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK551714/](https://www.ncbi.nlm.nih.gov/books/NBK551714/)  
58. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis, accessed on May 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/21407188/](https://pubmed.ncbi.nlm.nih.gov/21407188/)  
59. Sulfasalazine and 5-Aminosalicylates (5-ASA) \- IBD Journey \- Treatment and Medications \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Sulfasalazine-and-5-Aminosalicylates-5-ASA](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Sulfasalazine-and-5-Aminosalicylates-5-ASA)  
60. Side Effects From Ulcerative Colitis Medications \- WebMD, accessed on May 27, 2025, [https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-medications-side-effects](https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-medications-side-effects)  
61. Medical Treatment of Ulcerative Colitis \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2780076/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2780076/)  
62. Steroids \- Crohn's & Colitis UK, accessed on May 27, 2025, [https://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/treatments/steroids](https://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/treatments/steroids)  
63. Systemic Steroids for Ulcerative Colitis \- WebMD, accessed on May 27, 2025, [https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/uc-systemic-steroids](https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/uc-systemic-steroids)  
64. A review of the therapeutic management of ulcerative colitis \- PMC \- PubMed Central, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9720837/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9720837/)  
65. Immunomodulators \- IBD Journey \- Treatment and Medications \- Immunosuppressants \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Immunomodulators](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Immunomodulators)  
66. Immunomodulators for all patients with inflammatory bowel disease ..., accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3002564/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3002564/)  
67. Is there room for immunomodulators in ulcerative colitis?, accessed on May 27, 2025, [https://www.tandfonline.com/doi/abs/10.1080/14712598.2020.1708896](https://www.tandfonline.com/doi/abs/10.1080/14712598.2020.1708896)  
68. IDDF2019-ABS-0336 Systematic review with meta-analysis: the efficacy of methotrexate in ulcerative colitis | Gut, accessed on May 27, 2025, [https://gut.bmj.com/content/68/Suppl\_1/A121.1](https://gut.bmj.com/content/68/Suppl_1/A121.1)  
69. Methotrexate for treatment of chronic active ulcerative colitis \- Cochrane, accessed on May 27, 2025, [https://www.cochrane.org/CD006618/IBD\_methotrexate-for-treatment-of-chronic-active-ulcerative-colitis](https://www.cochrane.org/CD006618/IBD_methotrexate-for-treatment-of-chronic-active-ulcerative-colitis)  
70. Biologics for ulcerative colitis: Types, side effects, cost, and more \- Medical News Today, accessed on May 27, 2025, [https://www.medicalnewstoday.com/articles/biologics-for-ulcerative-colitis](https://www.medicalnewstoday.com/articles/biologics-for-ulcerative-colitis)  
71. Which Biologics Treat Ulcerative Colitis (UC)? \- GoodRx, accessed on May 27, 2025, [https://www.goodrx.com/conditions/ulcerative-colitis/biologic-treatments](https://www.goodrx.com/conditions/ulcerative-colitis/biologic-treatments)  
72. accessed on January 1, 1970, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/medication-guide/biologic-therapies](https://www.crohnscolitisfoundation.org/patientsandcaregivers/medication-guide/biologic-therapies)  
73. How effective are biologics for ulcerative colitis? \- Drugs.com, accessed on May 27, 2025, [https://www.drugs.com/medical-answers/effective-biologics-ulcerative-colitis-3565624/](https://www.drugs.com/medical-answers/effective-biologics-ulcerative-colitis-3565624/)  
74. Studies identify promising new treatments for ulcerative colitis \- UChicago News, accessed on May 27, 2025, [https://news.uchicago.edu/story/studies-identify-promising-new-treatments-ulcerative-colitis](https://news.uchicago.edu/story/studies-identify-promising-new-treatments-ulcerative-colitis)  
75. Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis \- PubMed, accessed on May 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/39182898/](https://pubmed.ncbi.nlm.nih.gov/39182898/)  
76. Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis | Inflammatory Bowel Diseases | Oxford Academic, accessed on May 27, 2025, [https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izae163/7732940?searchresult=1](https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izae163/7732940?searchresult=1)  
77. Long-term Safety and Adverse Events ... \- Expert Perspectives, accessed on May 27, 2025, [https://expertperspectives.com/long-term-safety-and-adverse-events-associated-with-ulcerative-colitis-therapies/](https://expertperspectives.com/long-term-safety-and-adverse-events-associated-with-ulcerative-colitis-therapies/)  
78. JAK inhibitors \- IBD Journey \- Treatment and Medications \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/JAK-inhibitors](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/JAK-inhibitors)  
79. Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence \- MDPI, accessed on May 27, 2025, [https://www.mdpi.com/1424-8247/18/3/308](https://www.mdpi.com/1424-8247/18/3/308)  
80. JAK inhibitors for ulcerative colitis \- Medical News Today, accessed on May 27, 2025, [https://www.medicalnewstoday.com/articles/jak-inhibitors-ulcerative-colitis](https://www.medicalnewstoday.com/articles/jak-inhibitors-ulcerative-colitis)  
81. Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review \- MDPI, accessed on May 27, 2025, [https://www.mdpi.com/2227-9059/11/3/747](https://www.mdpi.com/2227-9059/11/3/747)  
82. The Cell-Specific Effects of JAK1 Inhibitors in Ulcerative Colitis \- MDPI, accessed on May 27, 2025, [https://www.mdpi.com/2077-0383/14/2/608](https://www.mdpi.com/2077-0383/14/2/608)  
83. A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATI \- ClinicalTrials.gov, accessed on May 27, 2025, [https://cdn.clinicaltrials.gov/large-docs/04/NCT03281304/Prot\_001.pdf](https://cdn.clinicaltrials.gov/large-docs/04/NCT03281304/Prot_001.pdf)  
84. Vitamin and Mineral Supplementation | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/supplementation](https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/supplementation)  
85. Indications and Options for Surgery in Ulcerative Colitis \- Cloudfront.net, accessed on May 27, 2025, [https://d1xe7tfg0uwul9.cloudfront.net/cbc-portal/wp-content/uploads/2016/01/122015SCNAio.pdf](https://d1xe7tfg0uwul9.cloudfront.net/cbc-portal/wp-content/uploads/2016/01/122015SCNAio.pdf)  
86. Surgery for Ulcerative Colitis | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/surgery](https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/surgery)  
87. Colectomy \- Mayo Clinic, accessed on May 27, 2025, [https://www.mayoclinic.org/tests-procedures/colectomy/about/pac-20384631](https://www.mayoclinic.org/tests-procedures/colectomy/about/pac-20384631)  
88. Ulcerative Colitis: Should I Have Surgery? \- MyHealth Alberta, accessed on May 27, 2025, [https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=uf4785](https://myhealth.alberta.ca/Health/pages/conditions.aspx?hwid=uf4785)  
89. my.clevelandclinic.org, accessed on May 27, 2025, [https://my.clevelandclinic.org/health/diseases/10351-ulcerative-colitis\#:\~:text=Does%20ulcerative%20colitis%20ever%20go,is%20achieving%20and%20maintaining%20remission.](https://my.clevelandclinic.org/health/diseases/10351-ulcerative-colitis#:~:text=Does%20ulcerative%20colitis%20ever%20go,is%20achieving%20and%20maintaining%20remission.)  
90. J-Pouch: What It Is, Surgery & Complications \- Cleveland Clinic, accessed on May 27, 2025, [https://my.clevelandclinic.org/health/treatments/21062-j-pouch-surgery](https://my.clevelandclinic.org/health/treatments/21062-j-pouch-surgery)  
91. Ulcerative Colitis J-Pouch Surgery Success Rates \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/j-pouch-surgery-success-rates](https://www.healthline.com/health/ulcerative-colitis/j-pouch-surgery-success-rates)  
92. Quality of life in patients with ulcerative colitis treated surgically \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4178048/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4178048/)  
93. J-Pouch Surgery | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/surgery/j-pouch-surgery](https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis/surgery/j-pouch-surgery)  
94. 6 Tips for Recovering from J-Pouch Surgery for Ulcerative Colitis \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/recovering-from-j-pouch-surgery](https://www.healthline.com/health/ulcerative-colitis/recovering-from-j-pouch-surgery)  
95. Long-term mental and physical quality of life outcomes following ileal pouch anal anastomosis surgery \- RCSEng, accessed on May 27, 2025, [https://publishing.rcseng.ac.uk/doi/full/10.1308/rcsann.2023.0075?utm\_campaign=2862625\_Annals+eTOC+January+2025\&utm\_medium=dotmailer\&dm\_i=4D4N%2C1PCTD%2C1182R1%2C7ZLVK%2C1\&utm\_source=emailmarketing](https://publishing.rcseng.ac.uk/doi/full/10.1308/rcsann.2023.0075?utm_campaign=2862625_Annals+eTOC+January+2025&utm_medium=dotmailer&dm_i=4D4N,1PCTD,1182R1,7ZLVK,1&utm_source=emailmarketing)  
96. Managing ulcerative colitis after surgery \- Frontiers, accessed on May 27, 2025, [https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1081940/full](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1081940/full)  
97. Frequency of extraintestinal manifestation (EIM) before and after... \- ResearchGate, accessed on May 27, 2025, [https://www.researchgate.net/figure/Frequency-of-extraintestinal-manifestation-EIM-before-and-after-colectomy-Pie-charts\_fig2\_354125641](https://www.researchgate.net/figure/Frequency-of-extraintestinal-manifestation-EIM-before-and-after-colectomy-Pie-charts_fig2_354125641)  
98. Long-term outcome and quality of life after continent ileostomy for ulcerative colitis: A systematic review \- PubMed, accessed on May 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/34166559/](https://pubmed.ncbi.nlm.nih.gov/34166559/)  
99. Eating and Drinking with IBD \- IBD Journey \- Diet and Nutrition ..., accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diet-and-Nutrition-in-IBD/Eating-and-Drinking-with-IBD](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Diet-and-Nutrition-in-IBD/Eating-and-Drinking-with-IBD)  
100. Diet For Ulcerative Colitis: Foods To Eat & Avoid \- Local Infusion, accessed on May 27, 2025, [https://mylocalinfusion.com/foods-to-eat-and-avoid-with-ulcerative-colitis/](https://mylocalinfusion.com/foods-to-eat-and-avoid-with-ulcerative-colitis/)  
101. Ulcerative Colitis Diet, Meal Planning, and Foods to Eat and Avoid \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis-take-control/diet-plan-recipes](https://www.healthline.com/health/ulcerative-colitis-take-control/diet-plan-recipes)  
102. Inflammatory Bowel Disease (IBD): Crohn's Disease and Ulcerative Colitis Nutrition Therapy \- Huron Gastro, accessed on May 27, 2025, [https://www.hurongastro.com/assets/1/6/IBD\_Nutrition\_Therapy.pdf](https://www.hurongastro.com/assets/1/6/IBD_Nutrition_Therapy.pdf)  
103. IBD Aid & Keto Diets for Ulcerative Colitis \- WebMD, accessed on May 27, 2025, [https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-and-diets](https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/ulcerative-colitis-and-diets)  
104. Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know? \- PMC, accessed on May 27, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8100370/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8100370/)  
105. What Should I Eat? | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/what-should-i-eat](https://www.crohnscolitisfoundation.org/patientsandcaregivers/diet-and-nutrition/what-should-i-eat)  
106. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review \- PubMed, accessed on May 27, 2025, [https://pubmed.ncbi.nlm.nih.gov/38276922/](https://pubmed.ncbi.nlm.nih.gov/38276922/)  
107. Ulcerative Colitis and Low FODMAP Diet: Can It Help? \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/low-fodmap-diet-ulcerative-colitis](https://www.healthline.com/health/ulcerative-colitis/low-fodmap-diet-ulcerative-colitis)  
108. Special IBD Diets \- Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientandcaregivers/diet-and-nutrition/special-ibd-diets](https://www.crohnscolitisfoundation.org/patientandcaregivers/diet-and-nutrition/special-ibd-diets)  
109. The Specific Carbohydrate Diet \- Romanwell, accessed on May 27, 2025, [https://www.romanwell.com/blog/the-specific-carbohydrate-diet](https://www.romanwell.com/blog/the-specific-carbohydrate-diet)  
110. Use of Specific Carbohydrate Diet in a Severe Case of Ulcerative Colitis \- ResearchGate, accessed on May 27, 2025, [https://www.researchgate.net/publication/352629270\_Use\_of\_Specific\_Carbohydrate\_Diet\_in\_a\_Severe\_Case\_of\_Ulcerative\_Colitis](https://www.researchgate.net/publication/352629270_Use_of_Specific_Carbohydrate_Diet_in_a_Severe_Case_of_Ulcerative_Colitis)  
111. IBD Journey \- Treatment and Medications \- Enteral Nutrition (EEN), accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Enteral-Feeding](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Treatment-and-Medications/Enteral-Feeding)  
112. Omega 3 fatty acids (fish oil) for maintanence of remission in ulcerative colitis | Request PDF, accessed on May 27, 2025, [https://www.researchgate.net/publication/6201363\_Omega\_3\_fatty\_acids\_fish\_oil\_for\_maintanence\_of\_remission\_in\_ulcerative\_colitis](https://www.researchgate.net/publication/6201363_Omega_3_fatty_acids_fish_oil_for_maintanence_of_remission_in_ulcerative_colitis)  
113. Omega 3 fatty acids for maintenance of remission in ulcerative colitis \- Cochrane, accessed on May 27, 2025, [https://www.cochrane.org/CD006443/IBD\_omega-3-fatty-acids-for-maintenance-of-remission-in-ulcerative-colitis](https://www.cochrane.org/CD006443/IBD_omega-3-fatty-acids-for-maintenance-of-remission-in-ulcerative-colitis)  
114. Stress | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/justlikeme/living-with-crohns-and-colitis/stress](https://www.crohnscolitisfoundation.org/justlikeme/living-with-crohns-and-colitis/stress)  
115. Exercise | Crohn's & Colitis Foundation, accessed on May 27, 2025, [https://www.crohnscolitisfoundation.org/patientsandcaregivers/campus-connection/navigating-college/exercise](https://www.crohnscolitisfoundation.org/patientsandcaregivers/campus-connection/navigating-college/exercise)  
116. Ulcerative colitis \- Living with \- NHS, accessed on May 27, 2025, [https://www.nhs.uk/conditions/ulcerative-colitis/living-with/](https://www.nhs.uk/conditions/ulcerative-colitis/living-with/)  
117. Mental health and wellbeing with Crohn's or Colitis, accessed on May 27, 2025, [https://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/living-with-crohns-or-colitis/mental-health-and-wellbeing](https://crohnsandcolitis.org.uk/info-support/information-about-crohns-and-colitis/all-information-about-crohns-and-colitis/living-with-crohns-or-colitis/mental-health-and-wellbeing)  
118. 9 Ways to Sleep Better with Ulcerative Colitis \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/ulcerative-colitis-sleep-tips](https://www.healthline.com/health/ulcerative-colitis/ulcerative-colitis-sleep-tips)  
119. Safe and Effective Exercise \- IBD Journey \- Exercise and Lifestyle \- Crohn's and Colitis Canada, accessed on May 27, 2025, [https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Exercise-and-Lifestyle/Therapeutic-Monitoring](https://crohnsandcolitis.ca/About-Crohn-s-Colitis/IBD-Journey/Exercise-and-Lifestyle/Therapeutic-Monitoring)  
120. Exercises for Ulcerative Colitis: Yoga, Running, and More \- Healthline, accessed on May 27, 2025, [https://www.healthline.com/health/ulcerative-colitis/exercises-yoga-running-swimming](https://www.healthline.com/health/ulcerative-colitis/exercises-yoga-running-swimming)  
121. CLINICAL STUDY PROTOCOL \- ClinicalTrials.gov, accessed on May 27, 2025, [https://cdn.clinicaltrials.gov/large-docs/69/NCT03996369/Prot\_000.pdf](https://cdn.clinicaltrials.gov/large-docs/69/NCT03996369/Prot_000.pdf)
